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INTRODUCTION 
Diabetes Mellitus currently affects more then 19.4 crore people 
worldwide and the figure is expected to reach 33.3 crore by 2025(33). India itself 
harbours over 3.5 crore diabetics which is the highest among the countries of 
the world and it is expected to touch 7.35 crore by 2025(33). These staggering 
figures unfortunately have earned India the title of “DIABETIC CAPITAL OF 
THE WORLD”. 
Diabetic foot ulcers are estimated to affect about 25% of all diabetics 
during their lifetime accounting for 20% of diabetic related hospitalisation. The 
risk of lower extremity amputation is 15-46 times higher in a diabetic and 
diabetic foot ulcers precede 85% of all foot amputations . Nine out of ten 
amputations are instigated by an infection. It is the spark that leads to 
amputation though circulation is critically important, it only determines the 
level of amputation.(33) 
The burden of diabetic foot ulcer is set to rise further in the future since 
contributory factors such as peripheral neuropathy and peripheral vascular  
disease are present in more than10% of diabetics at the time of diagnosis.(33) 
There is little awareness for foot care in patients and there is significant delay 
in seeking the treatment. Further a significant population in our country is rural 
and work in the fields barefoot, thus increasing the chances of further infection.  
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Prolonged or indiscriminate antibiotic use leads to drug resistance. 
Hence now we not only have multidrug resistant bacteria emerging but also 
fewer drugs which can be safely prescribed.  With the indiscriminate usage of 
antibiotics there is today emergence of mutidrug resistant organisms, leading in 
this regard are Methicillin resistant Staphylococci, (MRSA) Beta lactamase 
producing gram negative bacilli (ESBL), vancomycin resistant Enterococci 
(VRE) etc. 
Many of the MRSA strains are multidrug resistant and are susceptible 
only to glycopeptides ,antibiotics such as vancomycin. Therefore the 
knowledge of the prevelence of MRSA and their current antimicrobial profile 
becomes necessary in the selection of appropriate empirical treatment of these  
infections. 
The third generation cephalosporin like Cefotaxime, which became 
widely used for the treatment of serious infection due to gram negative bacilli, 
in 1980s were also called as Expanded Spectrum Antibiotics. Due to extensive 
use of these antibiotics, bacteria soon developed resistance, by means of a new 
β - lactamases and because of their increased spectrum of activity against most 
of the β-lactam antibiotics including third generation cephalosporins, these 
enzymes were called Extended Spectrum Beta Lactamases (ESBL).  
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There is paucity of data on the frequency of the emerging resistant 
strains causing infection and the outcome of such infections among diabetic 
foot ulcers in India.  
The present study aims to determine the microbiological and 
antimicrobial susceptibility profile of multidrug resistance organisms among 
diabetics. 
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AIMS AND OBJECTIVES 
1. To isolate and identify bacterial pathogen from diabetic foot ulcer. 
2. To study the antibiotic sensitivity pattern of the isolated bacterial 
pathogens. 
3. To assess the risk factors predisposing to diabetic foot ulcers.    
4. To characterise Methicillin resistant Staphylococcus aureus in the 
diabetic foot ulcer. 
5. To characterise Extended spectrum betalactamase producers among the 
Gram negative pathogens. 
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REVIEW OF LITERATURE 
India is home of nearly 33 million diabetics which is highest in the 
world out of which nearly 15% suffer from the dreaded sequel  of diabetic 
foot(33). Use of improper footwear and lack of knowledge regarding foot care 
attributes towards increase in the prevalence of diabetic foot.(33) 
In patients with diabetes the probability of infection in foot ulcer is five 
times greater than non diabetic patients.(34) The reduced availability of essential 
blood components in diabetic wound, severely impair healing. When deprived 
of  oxygen cells involved in wound healing die leading to the accumulation of 
devitalized tissue  that provides an ideal environment for the  growth of a 
diversity of micro organism.  Additionally ischemia and a dry environment 
interfere with delivery and activity  of polymorphonuclear cells in wound tissue, 
compromising the clearance of wound  microflora (34). 
PATHOPHYSIOLOGY 
A variety of physiologic and metabolic disturbances conspire to place 
diabetic patients at high risk for foot wounds. The various predisposing factors 
include metabolic derangements, faulty wound healing, neuropathy and 
vasculopathy . Microbial colonization of wounds is inevitable usually with 
endogenous bacteria, but these are potentially pathogenic in the wound 
environment. The risk of wound infection increases when local condition 
favour bacterial growth rather than host defence. Avoiding infection in a 
wound is most effectively achieved by clearing devitalized tissue and foreign 
bodies and ensuring adequate tissue perfusion. 
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Immunologic disturbances are also an important predisposing factor for 
infection. Among the defects in host immune defences  associated with 
diabetes are impairments of polymorphonuclear leukocyte functions, 
intracellular killing, and chemotaxis.  Many of these immunodceficencies are 
directly related to the metabolic perturbations caused by poorly controlled 
diabetes. The prevalence of these defects appears to be correlated, at least in 
part with the adequacy of glycaemia control. Ketosis in particular impairs 
leukocyte function.  Evidence suggests that in diabetic patients cellular immune 
responses and monocyte function are reduced.(33) 
Poor granuloma formation prolonged persistence of abscesses and 
impaired wound healing are further accompaniments of diabetes that may 
predispose to infectious complications. Diabetic patients also appear to have a 
higher rate of carriage of Staphylococcus aureus in their anterior nares and 
subsequently on the skin.(9) This colonization may predispose to skin infections 
with this virulent pathogen when there is a  break in the protective dermal 
surface. In addition several types of skin disorders as well as skin and nail 
fungal (Tinea) infections, disproportionately plague diabetic patients. In one 
study evidence of pedal fungal infection was found in over 80% of people with 
long term type I diabetes. Fungal infections provide breaks in the cutaneous 
envelope that then offer potential sites for bacterial invasions. The unique 
anatomy of the foot is among the reasons that infection is potentially so serious 
in this location. The structure of the various compartments, tendon sheaths and 
neurovascular bundles tends to favour the proximal spread of infection(36). 
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Poor blood glucose control contributes to increased mortality and 
mobility since hypoglycaemia is contributory to the development of infection 
and increased susceptibility to tissue injury(31). Neuropathy on the other hand 
predispose a diabetic to unrecognizable injury due to loss of sensation  It is 
therefore important to educate patients on preventive foot care  and remind 
physicians to examine the foot carefully on every visit.(31) 
MICROBIOLOGY OF FOOT ULCERS 
Many studies have reported on the bacteriology of diabetic foot 
infections (DFIs) over the past 25 years but the results have varied and have 
been contradictory. A number of studies have found that Staphylococcus 
aureus is the main causative pathogen but two recent investigations reported a 
predominance of gram negative aerobes.(32) The role of anaerobes  is 
particularity unclear because in many studies specimens are not collected or 
cultured properly to recover these organism(32). 
Previous studies have shown that when optimal specimen collection, 
transport and culture technique are used, multiple organism are usually 
recovered from DFIs. Furthermore some studies suggest that the interaction of 
organism within these polymicrobial mixture lead to the production of 
virulence factors such as hemolysins proteases and  collegenases as well as 
short chain fatty acids, that cause inflammation, impede wound healing and 
contribute to the chronicity of the infection in such mixtures, biofilm that 
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impede the penetration of antimicrobial agents into the infected site may also 
form, thus the presence of multiple species can have important clinical 
implication that should not be over looked (69) 
The skin being coated with bacteria  present in a harmless associations  
will rapidly  colonize disrupted epithelium and microbial multiplication ensues, 
with local tissue destruction and release of bacterial toxins inciting a host 
response the wound is now defined as infected.                                                             
Infection may either follow colonization or occur as a primary event for 
example in the setting of acute trauma. Infection involves the invasion of host 
tissues by microorganisms (Pathogens) with a subsequent host inflammatory 
response (erythema, induration, pain or tenderness ,warmth loss of function and 
purulent secretions.)In diabetes the colonizing flora become more complex; 
virulent aerobic gram-positive cocci notably S. aureus and B-hemolytic 
streptococci may flourish. Antibiotic therapy can also alter the colonizing flora 
of skin or  wounds, favouring organisms that are resistant to the agent 
administered.  
Lesions that have been infected for a short time tend to be 
monomicrobial and to be caused by gram positive pathogens. Chronic wounds 
develop complicated flora with aerobic gram negative rods, anaerobes (gram 
positive and negative) and enterococci in addition to the gram positive aerobes. 
Fungi (including Candida and Tinea species) also appear to disproportionately 
colonize the skin of diabetic patients.(69) 
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Foot infections are generally polymicrobial. Cultures from these 
infections yield on average 4.1 - 5.8 bacterial species per culture. Both gram 
positive cocci and gram negative rods are commonly isolated from a single 
lesion, and in 40% of infections both aerobic and anaerobic organisms are 
recovered.(69) Individual cultures have yielded on average 2.9 - 3.5 aerobes and 
1.2 – 2.6 anaerobes S. aureus, streptococci and facultative gram negative bacilli 
Proteus species, Enterobacter species, Escherichia coli and Klebsiella species) 
are the predominant aerobic pathogens in these infections.(71) Among the 
anaerobes Peptostreptococcus species, Prevorella species and Bacteroides 
species including those of the B.fragilis group are recovered frequently. 
Clostridium species are recovered infrequently. 
The spectrum of bacterial species recovered from foot infections, 
especially those that are limb threatening, can be dramatically altered by prior 
failed antimicrobial therapy whereas Pseudomonas aeruginosa, Acinetobacter 
species and other antibiotic resistant facultative gram-negative bacilli are 
uncommon in previously untreated infections these organisms are not 
infrequent isolate from infected chronic ulcers . Similarly methicillin-resistant 
S.aureus may be encountered commonly in patients with chronically infected 
foot ulcers that have persisted in spite or multiple prior courses of antimicrobial 
therapy. These resistant bacteria are probably acquired nosocomially or 
alternatively emerge from endogenous flora during the repetitive 
hospitalization and antibiotic treatment of patients with non healing foot ulcers. 
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Accordingly, when selecting an antimicrobial regimen to treat a foot infection 
in a patient who has had multiple hospitalizations and prior courses of 
antibiotics, physicians should anticipate the presence of antibiotic resistant 
pathogens.(69) 
The role of relatively avirulent bacteria many of which are part of skin 
flora that are often isolated from cultures of specimens obtained through an 
ulcer is uncertain. Staphylococcus epidermidis has been recovered usually in 
conjunction with other bacteria from 15-35% of these infections and may not 
reflect ulcer colonization.(69) On the other hand S.epidermidis has been isolated 
from reliable foot specimens with similar frequency to S.aureus suggesting that 
these organisms may be pathogens in some patients .Enterococci variants 
streptococci and Corynebacterium species, organisms that are often considered 
contaminants and not pathogens when isolated from skin and soft tissue 
infections, are among the isolates recovered frequently from polymicrobial 
limb threatening foot infections. When recovered from specimen in conjunction 
with typical pathogens these organisms are often disregarded as contaminants. 
Often, foot infections respond to therapy with antimicrobials that are active in 
vitro against the pathogens but not against these presumed contaminants. 
Although these observations support the designation of these organisms as 
contaminants, they could also indicate that with the eradication of major 
pathogens, host defences and surgical debridement can control these less 
virulent organisms.(69) 
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THE INFECTED FOOT ULCER 
Diabetic foot ulcer are not spontaneous ulcer but result from the 
interplay of various factors like peripheral neuropathy, autonomic neuropathy 
and peripheral vascular disease are superimposed with alteration in the plantar 
pressure, defective footwear and limited joint mobility. Cell mediated 
immunity is most affected with abnormality of polymorphonuclear leucocytes, 
monocytes and lymphocytes.(33) 
Clinical assesment of the ulcer include description of location, 
appearance,  extent, depth temperature and odour. Infected wounds may appear  
purple or red or even brown or black, depending on the pathogen and its 
aetiology and their drainage may be serous, hemorrhagic or purulent. 
Induration of the skin and swelling denotes infection which usually raises skin 
temperature. Foul odour of the ulcer may denote infection by a specific 
pathogen such as Proteus spp, Pseudomonads or anaerobes, a mixed infection 
or fungi or simply a necrotic process. Wound infection are categorized  as mild, 
moderate or severe.  
Mild infections are superficial infections confined to the skin and the 
subcutaneous fat with minimal or no purulence or cellulites, moderate 
infections are deep and may involve fascial muscle, tendon, joints or bones. 
They may present as cellulitesA of 0-2 cm in diameter or as a plantar abscess 
and they may cause systemic symptoms. They impose a certain risk of 
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amputation. Severe infection of a foot ulcer is a deep infection with more than 
2cm of cellulites lymphangitis, gangrene and causing systemic toxicity (36). All 
diabetic foot are classified and grouped according to Wagner grading system. 
In the Wagner’s classification system foot lesions are divided into six grades 
based on the depth of the wound and the extent of tissue necrosis.  Failure of 
the Wagner’s classification to specially address infection and ischemic within 
each grade has been recognized and a hybrid scheme has been developed to 
account for their important attributes to foot ulcers. 
A simplified system which only attached modifies for ischemia (A)  and 
infection  (B) is currently followed universally. 
MODIFIED WAGNER’s CLASSIFICATION SYSTEM (35) 
GRADE LESION 
O - No open lesion may have deformity or cellulites 
0  - A ischemic  
0  - B infected 
1 - superficial ulcer 
1  - A ischemic 
1  - B infected 
2 - deep ulcers to tendon or joint capsule 
2  -  A ischemic 
2  - B infected 
3 - Deep ulcers with abscess and osteomyelitis  
3  - A Ischemic 
3  - B infected 
4 - Localized gangrene- forefoot or heel 
4  - A Ischemic 
4  - B infected 
5 - Gangrene or entire foot 
5  - A Ischemic 
5  - B Infected. 
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The decision regarding proper management of diabetic foot infection is 
a difficult one and still a matter of debate. While optimal therapy is yet to be 
established most authors agree that the management of these infection require 
isolation and identification of the microbial flora, appropriate antibiotic therapy 
according to the susceptibility pattern, proper selection and identification of the 
chronic complications and proper surgical intervention with adequate 
glycaemia control. As most of the diabetic foot infection are polymicrobial in 
nature, mixed organisms are frequently encountered with emergence of 
resistance among organisms against the commonly used antibiotics due to their 
indiscriminate use. 
 Methicillin resistant Staphylococcus aureus(MRSA) has been a 
pathogen of concern in patients with Diabetic foot infections(DFIS) for almost 
two decades. In fact the first two  isolates of vancomycin resistant MRSA 
strains were from diabetic patients with foot  lesions, more recently  the 
emergence of community acquired MRSA has been noticed (32). Recent studies 
from India have reported prevalence of Extended spectrum 
betalactamases(ESBL) producers to be as high as 68%, Babypadmini et al 
(2004) have shown 40% of K pnemonia isolates and 41% of E coli isolates to 
be ESBL producers,   the  studies from Brazil show only 6%  of ESBL 
producers in diabetic foot infections. Antipapal et al have however reported 
54.5% isolates  to be ESBL producers which have caused diabetic foot ulcers. 
Thus the prevalence of MRSA AND ESBL constitutes a serious threat to the 
current antibiotics therapy leading to treatment failure and consequent 
escalation of costs. (39)  
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THE EMERGENCE OF MRSA 
Resistance to methicillin and other penicillin was first observed in S. 
aureus soon after methicillin was introduced into clinical use in Britain. The 
methicillin  resistant strains isolated in Britain at that time came from 
hospitalized patients and were multiple antibiotic resistant. They belonged to 
phage group III and their resistance to methicillin was heterogenous affecting 
only a minority of cell populations. 
After the mid 1970s large out breaks of infection by MRSA were 
recorded in many hospitals. Many of these out breaks appear to have been 
caused by a single epidemic strain that was transferred between hospitals by the 
movement of patients. A nomenclature has been developed to differentiate 
strains associated with epidemic MRSA from those associated with sporadic 
infection  . 
MRSA  in INDIA 
One of the earliest report from India was in 1982 when an incidence of 
6.6% was reported by Bhatia et al. In 1996 pullimood et al from Vellore 
reported an MRSA isolation rate of 24%, Uday shankar et al reported the figure 
as 20% from Pondicherry. 
A systematic study done in Delhi over six month period by Krishna 
prakash et al in 2001 reported on  MRSA isolation rate of 38.6%, in 2003 
hanumanthappa et al reported an isolation rate of 43% a higher rate of 54.85% 
has been reported in the same year by Anupurba et al from Banaras. 
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Patients with MRSA  have also been shown to be at increased risk for 
delayed treatment. Inappropriate antibiotic choices also has been associated 
with  higher hospital mortality rate(4) furthermore MRSA strain cause  
therapeutic problems because of their ability to develop resistance to other 
classes of  antibiotics including glycopeptides.(16) 
MECHANISM OF RESISTANCE  
Melhicillin resistance requires the presence of the chromosomally 
localized mec A gene. The mec A gene is responsible for the synthesis of 
penicillin  binding protein 2a (PBP 2a; also called PBP2) – a 78 KDa protein 
penicillin binding protiens (PBPS) are membrane bound enzyme that catalyze 
the transpeptidation reaction that is  necessary for cross linkage of 
peptidoglycan chains. PBP 2a  substitute for the other PBP s and because of its 
low affinity for all beta lactam antibiotics, it enables Staphylococcus to survive 
exposure to high concentration of these agents. Thus  resistance to methicillin 
confers resistance to all betalactam antibiotics including cephalosporins. PBP 
2a differs from other PBPs in that the active site blocks binding of all Beta-
lactams but allows the transpeptidation reaction to proceed. 
The mecA is part of a  genomic island designated staphylococcal 
cassette chromosome  (SCCmec ) To date four different SCCmec elements 
have been characterized. Health care associated MRSA(HA- MRSA) strain 
tend to carry SCC mec type I, II and III while the type IV element is generally 
carried by community associated MRSA (CA MRSA)(21) 
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Evidence available suggest a high frequency of a single clonal subgroup 
ST 239 to be the isolated strain from nine Asian countries from Saudi Arabia to 
the Philippine (19) This genotype has been characterized using Multilocus 
sequence typing (MLST) as HA- MRSA isolated from mainland Asia. Two 
recent reports noted an association between ST 239  and increased virulence.(14) 
Community associated MRSA (CA MRSA) has been defined both 
epidemiologically and molecularly. They have been typed as USA 300 and 400 
using pulsed field gel electrophoresis CA MRSA typically also has a 
characteristic antibiotic susceptibility pattern, carries specific virulence factor 
such as the panton - valentine  leukocidin (PVL) and posesses   a specific SCC 
mec type IV.(8,17) 
LABORATORY DIAGNOSIS OF MRSA: 
Detection of S.aureus 
Isolation of staphylococci from clinical specimen performed using blood 
agar plates followed by incubating at 35c - 37 C for 18 - 24 hrs .  Most 
staphylococcal species will produce abundant growth and the colonies are 
usually 1-3 mm in diameter, golden yellow pigmented, hemolytic, circular, 
smooth  and raised with a butyrous in consistency. 
S.aureus is identified by its colony morphology. Grams stain 
demonstrates the presence of gram positive cocci in clusters  and it also gives a 
positive catalase test. 
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S.aureus strains are usually identified using phenotypic and genotypic 
methods: 
Conventional methods of detection of MRSA: 
1. DISC DIFFUSION METHODS 
Oxacillin disc (lug)(50) 
Disc diffusion test is performed with lug of oxacillin per disc on 25 ml 
of Mueller-Hinton agar with NaCl supplementation. The zone of inhibition is 
determined after 24hrs of incubation at 37.c The zone size is interpreted 
according to CLSI guidelines. 
 SUSCEPTIBLE  - > 13 mm 
 INTERMEDIATE           - 11-12mm 
 RESISTANT  - <10mm 
Cefoxitin disc(30ug) diffusion test(1) 
Cefoxitin, a cephamycin is a more potent inducer of the mec A 
regulatory system than are the penicillins. Several groups of investigators have 
reported that the results of cefoxitin disc diffusion tests correlate better with the 
presence of mec A than do the results of disk diffusion  tests using oxacillin.(50) 
Based on a large number of data CLSI subcommittee on 
ANTIMICROBIAL SUSCEPTBILITY TESTING (CLSI – AST) adopted the 
use of the cefoxitin disc diffution test for predicting mec A mediated oxacillin 
resistance in Staphylococci and added a section for the test to table 2 C( the 
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Staphylococcal table) in both the  disc diffusion (M2) and MIC (M7) 
SECTION of CLSI documents M100 – S14(1) 
The  test is performed with 30 ug of cefoxitin per disc on 25ml Muller 
Hinton agar without NaCl supplementation. The zone of inhibition is 
determined after 24 hrs of incubation at 37C.The zone size is interpreted 
according to CLSI guidelines. 
 Susceptible   >19mm 
 Resistant   <20mm 
2) MIC DETERMINATION 
1) Agar dilution method (24) 
The inoculum is prepared by emulsifying portions of 4-5 discrete 
colonies into 4-5 ml of nutrient broth turbidity  adjusted by Mc Farlands 
standard 0.5. An aliquot of  1 in 20 dilution with normal saline (0.0001 ml) is 
used as the final inoculum. The concentrations of oxacillin used is 32ug-0.015 
ug/ml. The plates are dried before they are inoculated. The inoculum is applied 
as a spot of about 5-8 mm in diameter. A platinum loop calibrated to deliver 
0.001 ml of inoculum is used. The plates are then incubated for 24hrs at 37.c. 
The endpoint is the concentration of the antibiotic completely inhibiting the 
growth. The results are as the MIC value in ug/ml 
 Susceptible   < 2ug/ml 
 Resistant > 4ug/ml 
2)        broth dilution method 
          Micro dilution method 
 Macro dilution method 
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Serial dilution of oxacillin is added to Mueller Hinton broth with 4% 
NaCl. A  young peptone water culture of S aureus corresponding to 0.5 Mc 
farland turbidity is used as the inoculum and it is incubated at 33-35 C for 24 
hrs. 
 Oxacillin MIC  < 2 ug/ml    -Susceptible 
    > 2ug/ml – resistant 
3) E – Test method 
 E – Test also known as the epsilometer test is an exponential gradients 
testing methodology where E in E test refers to the greek symbol epsilon. The 
E test which is a quantitative method for antimicrobial susceptibility testing 
applies both the dilution of antibiotic and diffusion of antibiotic into the 
medium. A pre defined  stable antimicrobial gradient is present on a thin inert 
carrier strip. When this E test strip is applied onto an inoculated agar plate there 
is an immediate release of the drug. Following incubation a symmetrical 
inhibition eclipse is produced  The intersection of the inhibitary zone edge and 
the calibrated carrier strip indicates the MIC value over a wide concentration 
range with inherent  precision and accuracy. 
4) Latex agglutination test for detection of PBP 2a 
 A loop full of bacterial cells are suspended in 200 ul of extraction 
reagent and subsequently lysed by boiling for 3 min, after cooling to room 
temperature  50ul of another extraction  reagent is added to 200ul of the lysate 
and mixed well. After 1 min of centrifugation at 1500 x g rpm 40 ul of the 
supernatant is used for testing agglutination with sensitised latex particles (1 
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drop) The test card is rotated for 3 min and the resulting agglutination patterns 
are usually read. 
NEWER METHODS 
SCREENING TEST 
Mannitol salt agar- cefoxitin screening medium(2) 
Mannitol salt agar(MSA) plates are prepared with cefoxitin at 
concentrations of 2,3 or 4 mg/liter. The test strains are applied by using fresh 
overnight cultures on blood agar matched to 0.5 Mc farland standard. 
Incubation is carried out at 35 c to 37c for 48 hrs and results are read at 18 hrs 
and 48 hrs. 
The growth of any visible colonies after incubation is recorded as 
positive result. 
CHROMagar MRSA(9)  
It combines primary isolaton from clinical specimen with direct 
identification of MRSA in one step.On this  agar MRSA isolates appear as light 
mauve to mauve colonies at 16 to 18 hrs of incubation. Others  will appear as 
white or beige or grow poorly. 
GENOTYPIC METHODS: 
1) Multiplex PCR for MRSA 
a) Detection of mecA and fem B genes 
b) Detection of  mecA and Coag genes 
c) Detection of mecA and ccr genes 
d) Detection of mecA and nuc genes 
e) Detection of toxin genes (PvL genes) 
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2) REAL – TIME PCR 
Real time PCR assays are used to detect MRSA directly from positive 
blood culture bottles .The assay differentiates MRSA into clusters on the basis 
of melting curve analysis. 
3) Pulsed- fieid gel eletrophoresis:(5) 
A bacterial pellet obtained from an overnight grown culture of a single 
colony is processed and the restriction fragments are seperatedon gel. Gel is 
stained with ethidium bromide and photographed under UV light. 
Strain relatedness among CA-MRSA and HA-MRSA isolates can be 
investigated. 
4) Multi Locus Sequence Typing (MLST)(5) 
MLST is useful for investigating the clonal evolution of MRSA It is 
based on sequence analysis from seven S.aureus housekeeping genes 
i.e.,arcC,aroE,glpF,gmk,pt,tpi and yqiL.Each isolate is defined by all the alleles 
of the seven genes. This results in an allelic profile or gene sequence type(ST) 
5) Microarray Analysis:(10) 
Multiplex PCR products can be used as hybridization samples. After 
hybridization at the test site of the microarray, fluorescence detection is 
performed automatically by the instrument images of the array is then captured 
automatically and analysed using the image analysis software of the instrument. 
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MANAGEMENT OF MRSA INFECTIONS 
Vancomycin is the drug of choice for serious infection caused by 
methicillin resistant Staphyloccocus aureus.(3) 
Vancomycin and teicoplanin are glycopeptide antibiotics used to treat 
MRSA infections.  Teicoplanin is a structural congener of vancomycin that has 
a similar activity spectrum but a longer half-life.  Because the oral absorption 
of vancomycin and teicoplanin is very low, these agents must be administered 
intravenously to control systemic infections. Treatment of MRSA infection 
with vancomycin can be complicated, due to its inconvenient route of 
administration.  
Several newly discovered strains of MRSA show antibiotic resistance 
even  to vancomycin and teicoplanin. These new evolutions of the MRSA 
bacterium are called Vancomycin intermediate-resistant Staphylococcus aureus 
(VISA). Linezolid, quinupristin/dalfopristin, daptomycin, and tigecycline are 
used to treat more severe infections that do not respond to glycopeptides such 
as vancomycin.  
Treatments in clinical trials 
It has been reported that maggot therapy to clean out necrotic tissue of 
MRSA infection has been successful. Studies in diabetic patients reported 
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significantly shorter treatment times. Many antibiotics against MRSA are in 
phase II and phase III clinical trials. eg: 
• Phase III : ceftobiprole, Ceftaroline, Dalbavancin, Telavancin, Aurograb, 
torezolid, iclaprim...  
• Phase II : nemonoxacin.  
Pre-clinical research 
An entirely different and promising approach is phage therapy  which in 
mice had a reported efficacy against up to 95% of tested Staphylococcus 
isolates. On May 18, 2006, a report in Nature identified a new antibiotic, called  
platensimycin, that had demonstrated successful use against MRSA.  
Prevention and infection-control strategies 
Screening programs 
Patient screening upon hospital admission, with nasal cultures, prevents 
the cohabitation of MRSA carriers with non-carriers, and exposure to infected 
surfaces.  
Surface sanitizing 
Alcohol has been proven to be an effective surface sanitizer against 
MRSA.  
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Quaternary ammonium compounds can be used in conjunction with 
alcohol to extend the longevity of the sanitizing action. The prevention of 
nosocomial infections involves routine and terminal cleaning.  
Hand washing 
Although alcohol-based rubs remain somewhat effective, a more 
effective strategy is to wash hands with running water and an anti-microbial 
cleanser with  persistent killing action, such as Chlorhexidine. 
Decolonization 
After the drainage of boils or other treatment for MRSA, patients can 
shower at home using chlorhexidine or hexachlorophene  antiseptic soap from 
head to toe, and apply mupirocin (Bactroban) 2% ointment inside each nostril 
twice daily for 7 days, using a cotton-tipped swab. Household members are 
recommended to follow the same decolonization protocol.  
Proper disposal of hospital gowns 
Used paper hospital gowns are associated with MRSA hospital 
infections, which could be avoided by proper disposal.  
Restricting antibiotic use 
Glycopeptides, cephalosporins and in particular quinolones are 
associated with an increased risk of colonisation of MRSA. Reducing use of 
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antibiotic classes which promote MRSA colonisation, especially 
fluoroquinolones is recommended in current guidelines.  
The Emergence of ESBL 
Microbial resistance through extended-spectrum B-lactamase (ESBL) 
was first reported in the early 1980s in Europe and subsequently in the United 
States soon after the introduction of third-generation cephalosporins in clinical 
practice (58). Today, this resistance mechanism has emerged globally and 
ESBL-producing Enterobacteriaceae are recognized world wide as nosocomial 
pathogens of major importance (19, 28) Many clinical microbiology laboratories 
have problems with the detection of ESBL-mediated resistance, and the recent 
emergence and spread of novel types of community-acquired ESBLs, such as 
the CTX-M enzymes have created additional challenges that further complicate 
the detection of this resistance mechanism.(58) 
Resistance to third generation oxyimino-cephalosporins is mediated by 
extended spectrum B-lactamase enzymes (ESBLS) which are derivatives of 
narrow spectrum TEM and SHV B-lactamases capable of hydrolyzing 
oxyimino-cephalosporins (but not cephamycin such as cefoxitin and cefotetan). 
They are inhibited by clavulanic acid and are placed into Bush’s functional 
group 2be. The diversity for ESBLs results in various susceptibility profiles 
with different B-lactam antibiotics. Some variants (TEM-3 and-4) give high-
level resistance to all second and third generation cephalosporin’s while other 
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variants (TEM-10-12, and-26) give obvious resistance to ceftazidime but give 
moderate resistance to cefotaxime, ceftriaxone, and to the fourth generation 
cephalosporins. ESBL production is known commonly to occur in E. coli and 
Klebsiella but have also been found in other members of the 
Enterobacteriaceae family. (68) 
These enzymes are the result of mutations of Temorina (TEM-1 and 
TEM-2) and Suph hydryl variable (SHV-1) enzymes, usually plasmid mediated 
and are commonly found in the Enterobacteriaceae family. Some derivatives of 
TEM and SHV, which are not inhibited by clavulanic acid, are known as 
inhibitor resistant TEM (IRT) and the AmpC Class of enzymes, which are 
intrinsically resistant to clavulanic acid and are causing great concern as 
Carbapenems are the only antibiotic effective against such strains.(67) 
Bacterial resistance to carbapenems mediated by acquired  
carbapenemases represents an important problem worldwide (10,15). These 
carbapenemases can be classified into three molecular classes according to the 
Ambler scheme (15)A (Penicillinases), B (metallo-B-lactamases (MBLs)and D 
(Oxacillinases). The Mettalobetalactamases(MBL) producing variants of the 
types IMP, VIM, SPM-1, AND GIM-1 are thus far some of the most clinically 
relevant due to their ability to confer broad-spectrum B-lactam resistance, the 
unavailability of clinically useful inhibitors and their potential for rapid and 
generalized dissemination (23). This worrying situations prompts an early 
recognition of MBL producers for infections control and prevention of their – 
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generalized spread, in particular among emerging gram-negative, glucose non 
fermentative pathogens such as Pseudomonas spp. and Acinetobacter 
baumamii (15, 21) 
In recent years CTX-M extended-spectrum ß-lactamases (ESBLs) have 
very rapidly disseminated and are now frequently reported from countries all 
over Europe and much of Asia. More than 50 blaCTX-M genotypes are described.  
Epidemiological reports demonstrate that some enzymes are more 
frequently reported than others, that predominant enzyme type varies with 
country and that diverse CTX-M types often exist within a single country.  
In India, the very first report of the presence of CTX-M-producing 
Enterobacteriaceae came from New Delhi. Six isolates from 2000 were 
investigated, all of which were found to be unrelated and all produced CTX- 
M-15. Since then several Indian surveys have reported the presence of  ESBLs 
in clinical isolates based on phenotypic tests. Recent reported rates vary widely 
(12.6–71%), with most studies reporting a prevalence rate of around 50% and 
upwards. Considering a population of 1.1 billion in India, this represents a 
very large reservoir of resistance genes (61).  
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CLASSIFICATION OF BETA- LACTAMASE 
Classification schemes for bacterial beta-lactamases 
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1 1 Ia, Ib, Id CSase C Cephalosporins - - AmpC enzymes from 
gram-negative bacteria; 
MIR-1 
2a 2a Not included PCase V A Penicillins + - Penicillinases from 
gram-positive bacteria 
2b 2b III PCase I A Penicillins, 
cephalosporins 
+ - TEM-1, TEM-2, SHV-1
2be 2b’ Not included 
except K1 in 
class IV 
CXase A Penicillins, 
narrow- & 
extended-
spectrum 
cephalosporins, 
monobactams 
+ - TEM-3 to TEM-26, 
SHV-2 to SHV-6, 
Klebsiella oxytoca K1 
2br Not 
included 
Not included Not 
included 
A Penicillins +/- - TEM-30 to TEM-36, 
TRC-1 
2c 2c II, V PCase IV A Penicillins, 
carbenicillin 
+ - PSE-1, PSE-3, PSE-4 
2d 2d V PCase II, 
PCase III 
D Penicillins, 
cloxacillin 
+/- - OXA-1 to OXA-11, 
PSE-2 (OXA-10) 
2e 2e Ic CXase A Cephalosporins + - Inducible 
cephalosporinases from 
Proteus vulgaris 
2f Not 
included 
Not included Not 
included 
A Penicillins, 
cephalosporins, 
carbapenems 
+ - NMC-A from 
Enterobacter cloacae, 
Sme-1 from Serratia 
marcescens 
3 3 Not included Not 
included 
B Most b-lactams, 
including 
carbapenems 
- + L1 from Xanthomonas 
maltophilia, CcrA from 
Bac-teroides fragilis 
4 4 Not included Not 
included 
NDc Penicillins - ? Penicillinase from 
Pseudomonas cepacia 
 
a Csase, cephalosporinase; PCase, penicillinase; CXase, cefuroxime-
hydrolyzing b-lactamase. 
b CA, clavulanic acid. 
c ND, not determined. 
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Detection of ESBLs: 
I. Screening for ESBL producers-  
(i) Disc diffusion method: 
The CLSI has proposed disc diffusion methods for screening for ESBL 
production by Klebsiellae, Escherichia coli, and Proteus mirabilis. 
Laboratories using disc diffusion methods for antibiotic susceptibility testing 
can screen for ESBL production by noting specific zone diameters, which 
indicate a high level of suspicion for ESBL production. Cefpodoxime, 
ceftazidime, aztreonam, cefotaxime, or ceftriaxone is used. However, the use of 
more than one of these agents for screening improves the sensitivity of 
detection. If any of the zone diameters indicate suspicion for ESBL production, 
phenotypic confirmatory tests should be used to ascertain the diagnosis.  
(ii) Double-disc diffusion test 
In the late 1980s, French investigators described a disc diffusion test in 
which synergy between cefotaxime and clavulanate was detected by placing a 
disc of amoxicillin/clavulanate (20 μg/10 μg) and a disc of cefotaxime (30 μg), 
30 mm apart (center to center) on an inoculated agar plate. A clear extension of 
the edge of the cefotaxime inhibition zone toward the disc containing 
clavulanate was interpreted as synergy, indicating the presence of an ESBL;  
Clinical Laboratory Standards Institute (CLSI) Recommended Methods 
for ESBL Detection: 
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II. Phenotypic Confirmatory Tests for ESBL Production 
(i) Cephalosporin/clavulanate combination discs.  
The CLSI advocates use of cefotaxime (30 µg) or ceftazidime discs (30 
µg) with or without clavulanate (10 µg) for phenotypic confirmation of the 
presence of ESBLs in klebsiellae and Escherichia coli. The disc tests are to be 
performed with confluent growth on Mueller- Hinton agar. A difference of 5 
mm between the zone diameters of either of the cephalosporin discs and their 
respective cephalosporin/clavulanate disc is taken to be phenotypic 
confirmation of ESBL production.  
(ii) Broth microdilution  
Phenotypic confirmatory testing can also be performed by broth 
microdilution assays using ceftazidime (0.25 to 128 μg/ml), ceftazidime plus 
clavulanic acid (0.25/4 to 128/4 μg/ml), cefotaxime (0.25 to 64 μg /ml), and 
cefotaxime plus clavulanic acid (0.25/4 to 64/4 μg/ml). Again it should be 
emphasized that both ceftazidime and cefotaxime should be used. A 3-twofold-
serial-dilution decrease in MIC of either cephalosporin in the presence of 
clavulanic acid is compared to its MIC when tested alone. 
Implications of positive phenotypic confirmatory tests  
According to CLSI guidelines, isolates which have a positive phenotypic 
confirmatory test should be reported as resistant to all cephalosporins (except 
the cephamycins, cefoxitin, and cefotetan) and aztreonam, regardless of the 
MIC of that particular cephalosporin. 
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III. Commercially Available Methods for ESBL Detection 
(i) Etest for ESBLs  
AB Biodisk (Solna, Sweden) produces plastic drug-impregnated strips, 
one end of which contains a gradient of ceftazidime (MIC test range 0.5 to 32 
μg/ml) and the other with a gradient of ceftazidime plus a constant 
concentration of clavulanate (4 μg /ml). The reported sensitivity of the method 
as a phenotypic confirmatory test for ESBLs is 87 to 100% and the specificity 
is 95 to 100%. The manufacturer currently recommends a 8-fold reduction in 
cephalosporin MICs in the presence of clavulanate. 
(ii) Vitek ESBL cards  
Vitek ESBL test (bioMerieux Vitek, Hazelton, Missouri) utilizes 
cefotaxime and ceftazidime, alone (at 0.5 μg/ml), and in combination with 
clavulanic acid (4 μg/ml). Inoculation of the cards is identical to that performed 
for regular Vitek cards. Analysis of all wells is performed automatically once 
the growth control well has reached a set threshold (4 to 15 hours of 
incubation). A predetermined reduction in the growth of the cefotaxime or 
ceftazidime wells containing clavulanic acid, compared with the level of 
growth in the well with the cephalosporin alone, indicates a positive result. 
Sensitivity and specificity of the method exceed 90%. 
(iii) MicroScan panels  
Dade Behring MicroScan (Sacramento, Calif.) produces dehydrated 
panels for microdilution antibiotic susceptibility testing. 
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(iv) BD Phoenix Automated Microbiology System  
The Phoenix ESBL test uses growth response to cefpodoxime, 
ceftazidime, ceftriaxone and cefotaxime, with or without clavulanic acid, to 
detect the production of ESBLs. Results are usually available within 6 hours. 
In a study4 the test sensitivities for MicroScan ESBL plus ESBL 
confirmation panel was 100%, VITEK 1 GNS-120 99%, Etest ESBL 97% and 
BD BBL Sensi-Disk ESBL Confirmatory Test disks 96%. 
(v) Molecular ESBL detection techniques 
Test Advantages Disadvantages 
DNA 
probes 
Specific for gene family 
(e.g., TEM or SHV) 
Labor intensive, cannot distinguish between 
ESBLs and non-ESBLs, cannot distinguish 
between variants of TEM or SHV 
PCR Easy to perform, specific 
for gene family 
(e.g.,TEM or SHV) 
Cannot distinguish between ESBLs and non-
ESBLs, cannot distinguish between variants 
of TEM or SHV 
Oligotyping Detects specific TEM 
variants 
Requires specific oligonucleotide probes, 
labor intensive, cannot detect new variants 
PCR-RFLP Easy to perform, can 
detect specific nucleotide 
changes 
Nucleotide changes must result in altered 
restriction site for detection 
PCR-SSCP Can distinguish between 
a number of SHV 
variants 
Requires special electrophoresis conditions 
Nucleotide 
sequencing 
The gold standard, can 
detect all variants 
Labor intensive, can be technically 
challenging, can be difficult to interpret 
manual methods 
Real Time 
PCR 
Rapid identification, 
minimal cross 
contamination. 
Expensive, technical skill required 
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TREATMENT  OF INFECTIONS WITH ESBL-PRODUCING 
ORGANISMS 
ESBLs 
Strains producing only ESBLs are susceptible to cephamycins and 
carbapenems in vitro and show little if any inoculum effect with these agents. 
For organisms producing TEM and SHV type ESBLS, apparent in vitro 
sensitivity to cefepime and to piperacillin/tazobactam is common, but both 
drugs show an inoculum effect, with diminished susceptibility as the size of the 
inoculum is increased from 105 to 107 organisms. 
Strains with some CTX-M type and OXA type ESBLs are resistant to 
cefepime on testing, despite the use of a standard inoculum. 
Inhibitor-Resistant B-Lactamases 
Although the inhibitor-resistant TEM variants are resistant to inhibition 
by clavulanic acid and sulbactam, they remain susceptible to inhibiton by 
tazobactam and subsequently the combination of piperacillin/tazobactam. 
AmpC 
AmpC –Producing strains are typically resistant to oxyimino-beta 
lactams and to cephamycins and are susceptible to carbapenems how ever 
dimnished porin expression can make such a strain carbapenem-resistant as 
well. 
Carbapenemases 
Strains with IMP- VIM- and OXA type carbapenemases usually remain 
susceptible to aztreonam. 
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MATERIALS AND METHODS 
This is a descriptive study for a period of one and half year from July 
2008 to Dec 2009 to analyse the bacterial isolates from diabetic foot ulcers of 
patients attending the Department of diabetology, Kilpauk Medical college& 
Hospital.         
A total of 100 diabetic foot ulcer  patients from both sexes in age group 
between 35 to 82 years were studied during this period 
INCLUSION CRITERIA:- 
All diabetic patients with foot ulcers attending the department. 
EXCLUSION CRITERIA:- 
1. All non-diabetic patients with foot ulcers. 
2. All diabetic patients with foot ulcers but on antibiotic therapy. 
METHODOLOGY:-  
Methodology includes   
1. Collection of samples 
2. Identification of the organisms and antibiotic sensitivity pattern 
3. Selection of resistant strains 
4. Detection of  MRSA 
5. Identification of mecA gene 
6. Detection of ESBL production 
7. Identification of  CTX-M gene 
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SPECIMEN COLLECTION : 
Swab from diabetic foot ulcer :  
Wound area was wiped with sterile saline. Two sterile Swabs were 
rolled along leading edge of the wound, one for direct smear study and the 
other for aerobic bacterial culture. A bit of sough and tissue necrotic material 
from the base of the ulcer was inoculated into Robertson cooked meat broth. 
SPECIMEN TRANSPORT : 
The swabs were transported to the laboratory without delay. 
SPECIMEN PROCESSING 
Direct Gram Stained smear: 
One of the swabs was used for direct smear study using Gram stain. 
Aerobic culture : 
The other swab was used to plate the following culture plates. 
• 5% sheep Blood agar plate 
• MacConkey agar plate  
• Nutrient agar plate 
Anaerobic culture: 
After 48 hrs of incubation the Robertson cooked meat  broth was 
observed for signs of growth and then streaked onto anaerobic blood agar 
plates with hemin and Vit K supplement along with antibiotics. 
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Incubation 
The plates were incubated at 37degree centigrade for 24 hours for 
aerobic culture. Anaerobic plates were placed inside the polycarbonate jar 
along with Gaspak. Pseudomonas was used as biological control and methylene 
blue was used as a chemical indicator. The jar was left undisturbed for 48hrs. 
Identification of pathogens: 
After incubation the agar plates were analysed and every different 
looking colony was subjected to further processing . Gram stain was done for 
similar looking colonies. Pathogens were identified by growth on the basic 
plates and a battery of biochemical reactions as per standard laboratory 
protocol.   
Antibiotic sensitivity testing: 
Routine disc diffusion susceptibility testing of the strains was performed 
by modified Kirby Bauer Method  in Mueller-Hinton  agar  medium. To 
standardize the inoculam density for a susceptibility test, a Barium sulphate 
turbidity standard equivalent to a 0.5 McFarland standard was used. 
 Tip of 3-5 representative colonies were picked up and put in  4-5ml of 
nutrient broth and was incubated at 35˚ C until it matched in density with 0.5 
McFarland’s standard, which corresponds to 150 million organisms/ml.  
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 After 15 minutes of adjusting the turbidity of the inoculum suspension, a 
sterile cotton swab was dipped into it.  The swab was rotated several times and 
pressed firmly on the inside wall of the tube above the fluid level to remove 
excess broth from the swab. 
 Dried surface of Mueller Hinton agar plate was inoculated by swabbing  
over the entire sterile agar surface. The predetermined battery of antimicrobial 
discs  were dispensed on agar plates and pressed down to ensure complete 
contact with the agar surface. Discs were distributed evenly so that they were 
not closer than 24mm from centre to centre. Plates were inverted and incubated 
at 37oC for 16-18 hrs. 
After 16-18 hrs of incubation each plate was examined. The resulting 
zones of inhibition was uniformly circular and there was a semi-confluent lawn 
of growth. The diameter of the zones of complete inhibition was measured, 
including the diameter of the disc. Zones were measured to the nearest whole 
millimeter using a ruler which was held on the back of the inverted Petri plate.  
The sizes of the zones of inhibition were interpreted by referring to the 
CLSI standards and reported as susceptible, intermediate, or resistant to the 
agents that have been tested. 
Controls used  with each batch:- 
1. Escherichia coli   ATCC 25922 
2. Pseudomonas aeruginosa ATCC 27853 
3. Staphylococcus aureus  ATCC 25923  
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Detection of MRSA  strains 
Screening for MRSA: 
Oxacillin disc (1ug) 
Disc diffusion test is performed with lug of oxacillin  disc was placed on 
25 ml of Mueller-Hinton agar plate . The zone of inhibition is determined after 
24hrs of incubation at 37.c the zone size is interpreted according to CLSI 
guideline 
           SUSCEPTIBLE  - >13 mm 
 INTERMEDIATE           - 11-12mm 
 RESISTANT      -  < 10mm 
Cefoxitin disc(30ug) diffusion test 
The  test is performed with 30 ug of cefoxitin per disc placed on 25ml 
Muller Hinton agar plate without Nacl supplementation. The zone of inhibition 
is determined after 24 hrs of incubation at 37C. The zone size is interpreted 
according to CLSI guidelines. 
 Susceptible   >19mm 
 Resistant   < 20mm 
Quality control used for MRSA detection: 
ATCC S.aureus 43300 (positive control) 
ATCC S.aureus 25923 (negative control) 
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PCR FOR DETECTION OF mecA  gene(16,17) 
Preparation of cell lysate: 
0.1ml of a an overnight peptone water culture was centrifuged for 30 
seconds at 16000 rpm. Cells were then resuspended in 50 ul of lysostaphin 
(100ug/ml of water) and incubate at 37 c After 10 mins 50ul of proteinaseK 
solution (100ug/ml) and 150ul of TRIS buffer was added and reincubated for 
10 mins. It was placed in boiling waterbath for 10 mins. 2ul of the supernatent 
was used as the DNA sample for PCR 
Primer Sequence: 
MecA forward primer – 5’ AAAATCGATGGTAAAGGTTGGC-3’ 
MecA reverse primer  - 5’ AGTTCTGCAGTACCGGATTTGC-3’  
PCR: 
PCR cocktail was prepared according to the table tabulated below. To 
this cocktail 2 ul of the DNA sample is added PCR was set according to the 
following conditions: 
1. Initial  Denaturation for 5 mins  at 94º C.  
2. FOLLOWED BY 30 CYCLES 
3. Denaturation  for 30 secs at 94º C.  
4. Annealing for 30 secs at 55º C.  
5. Extension for 2min at 72◦C 
6. 10 min at 72º C for amplification.  
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Cocktail Procedure: 
S.no Reagents Amount to be added for 50ul 
1. WATER 38.5 
2. BUFFER 3 
3. Dntp 2 
4. TAQ POLYMERASE 0.5 
5. Primer-F +Primer-R 2 + 2 
6. DNA  2 
7. Total 50 
 
Gel Documentation:  
After the reaction, 10 µl. of the amplified samples were run on a 1.5 % 
agarose gel and electrophoresis done at 50 V with 1 x Tris Acetate EDTA 
buffer.  Amplicons were visualized using Ethidium bromide staining and 
scored using 100 bp DNA ladder as reference. 
Gels were viewed in a U - V gel documentation Unit and Photographed. 
A 533bp corresponds to mecA gene specific oligonucleotides.(16) 
Detection of ESBL 
Screening  for ESBL production 
All gram negative isolates that were resistant to at least two 3rd 
generation cephalosporin namely  cetriaxone(30mcg) and ceftazidime (30mcg) 
were considered to be probable ESBL producers and processed further for 
confirmation. (70) 
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(CLSI recommends MIC > 2µg/ml for cefotaxime, ceftazidime, 
astreonam, ceftriaxone (or) cefpodoxime as potential ESBL producers). 
2 indicators of ESBLs are  
i) 8 fold reduction in MIC when 3rd generation cephalosporins are used 
with clavulanic acid. 
ii) > 5mm increase in diameter of inhibition zone when using disc diffusion 
method with 3rd generation cephalosporin and clavulanic acid combined 
disc. 
1) Double-disc diffusion test  
In this test a disk of amoxicillin/ clavulanate (20 μg/10 μg) and a disk of 
cefotaxime (30 μg), 30 mm apart (center to center) was placed on an inoculated 
agar plate and incubated for 16 to 18hrs. A clear extension of the edge of the 
cefotaxime inhibition zone toward the disk containing clavulanate was 
interpreted as synergy, indicating the presence of an ESBL;  
2. Phenotypic Confirmation Test 
Lawn culture of the organism was made and 3rd generation 
cephalosporin, Ceftazidime (30µg) disc was tested alone and along with their 
combination for 10mg of clavulanic acid.  Organisms with 5mm increase in 
zone of inhibition for ceftazidime / clavulanic acid (30µg/10µg) are confirmed 
as ESBLs. 
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3) MIC determination : Done by agar dilution method. 
Preparation of media: Muller Hinton agar was prepared in tubes and 
autoclaved.  It is then allowed to cool in a 50oC water bath. 
Serial dilution of the 3 generation cephalosporins -  cefotaxime was 
prepared in sterile distilled water to give a final concentration ranging from 2μg 
– 2048μg/ml of agar. 
After adding the drug to the medium at 50o C it was mixed well and 
poured into sterile petridishes. (The media was used immediately otherwise 
potency of drugs will be affected.  We can inoculate upto 12 different 
organisms in a single plate). 
A control plate containing the test medium without the antibiotic was 
prepared for each series of test. 
Inoculum Preparation:  
At least 3-5 well isolated colonies of the same morphological type were 
selected from an agar culture plate. Top of each colony was touched with a 
loop and the growth was transferred into a tube containing 4-5ml of broth.  The 
broth culture was incubated at 37oC until it reaches 0.5 Mc Farland’s standard 
(usually 2-6 hrs). This result in growth corresponding to 150 million 
organisms/ml. 
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Minimum inhibitory concentration was the lowest concentration at 
which no visible growth occurs. 
Quality Control used for ESBL detection :  
Klebsiella pneumoniae ATCC 700603 [as positive control] 
Escherichia coli ATCC 25922 as negative control. 
4) MIC Reduction test: 
Isolates were tested for various concentrations of cephalosporin 
combined with 2ug/ml of clavulanic acid from 0.5ug to 2048ug / ml of agar 
and the MIC determined.  
An eight fold reduction in the MIC of 3rd generation  cephalosporins in 
the presence of clavulanic acid indicates production of ESBL. 
5) PCR procedure  for CTX- M  gene(61) 
Colony PCR technique was done in 13 isolates of  Klebseilla spp.to 
identify the commonly expressed  gene for resistance namely CTX-M 
A single colony of the test organism was picked up from a nutrient agar 
plate and inoculated  in 100 uL of distilled water, heated at 100◦c for 5min 
followed by centrifugation at 9000 rpm for 3min and then place in ice.  5ul of 
the centrifuged culture was added to the PCR cocktail mixture as given below. 
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Primer Sequence: 
CTX-M/F: 5'-CGCTTTGCGATGTGCAG-3’ 
CTX-M/R: 5'-ACCGCGATATCGTTGGT-3' 
PCR: 
1. Initial  Denaturation for 5 mins  at 94º C.  
2. FOLLOWED BY 30 CYCLES 
3. Denaturation  for 30 secs at 94º C.  
4. Annealing for 30 secs at 55º C.  
5. Extension for 1min at 72◦C 
6. 10 min at 72º C for amplification.                                  
COCKTAIL PROCEDURE: 
S.no Reagents Amount to be added 
for 50ul 
1. WATER 35.5 
2. BUFFER 3 
3. Dntp 2 
4. TAQ POLYMERASE 0.5 
5. Primer-F +Primer-R 2 + 2 
6. DNA CULTURE 5 
7. Total 50 
 
Gel Documentation:  
After the reaction, 25 µl. of the amplified samples were run on a 1.5 % 
agarose gel and electrophoresis done at 50 V with 1 x Tris Acetate EDTA 
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buffer.  Amplicons were visualized using Ethidium bromide staining and 
scored using 100 bp DNA ladder as reference. 
Gels were viewed in a U - V gel documentation Unit and Photographed. 
A 551 bp product corresponds to blaCTX-m  gene specific 
oligonucleotides.(61) 
Detection of Mettalobetalactamases (MBL) producing  Pseudomonas 
strains 
Screening for MBL producers 
All pseudomonas isolates which showed a zone of inhibition less than 
13mm around imipenam were considered to be carbapenam resistant (56) 
Combined disc synergy test (56) 
Two Imipenam (10ug) discs with a distance of 20mm between them 
were placed on the Mueller Hinton agar plate inoculated with the test 
strain.10ul of the inhibitor (EDTA) solution was added to one of the discs in 
the concentration of 750ug. After 24hrs of incubation period at 35degree C the 
increase (>7mm) of the inhibition zone obtained with the combined disk than 
the zone obtained with the Imipenam  disc alone was taken as a positive test. 
All the results obtained were statistically analysed and tabulated.  
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RESULTS 
Patients with diabetic foot ulcers attending the Institute of Diabetology 
at Kilpauk Medical College and Hospital, Chennai were studied for the 
presence of Methicillin resistant Staphylococcus aureus and Extended spectrum 
betalactamase producing isolates in the diabetic foot ulcers. The study was 
done between July 2008 and Dec 2009. 
100 patients with diabetic foot ulcer were studied and 142 bacterial 
isolates from the ulcers were isolated, identified and analysed for their 
antibiotic sensitivity pattern.   Resistant strains were identified and studied for 
Methicillin resistant Staphylococcus aureus (MRSA) and extended spectrum 
betalactamases (ESBL) producing bacteria by various methods. 
The observations were recorded and analysed. The results are as follows:   
CLINICAL DATA 
Table - I 
Demography of patients 
N = 100 
 
Characteristic Number of Patients Ratio 
Male 
Female 
53 
47 1: 0.8 
 
100 patients with diabetic foot ulcer were studied. Out of these 100 
patients included in the study 53 were male and 47 were female. The male to 
female ratio was 1: 0.8 
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Table II 
Age distribution 
N = 100 
Age No Male Female 
30-40 
 
40-50 
 
50-60 
 
60-70 
 
70-80 
 
above 80 
7
 
19 
 
32 
 
28 
 
13 
 
1
5
 
14 
 
16 
 
18 
 
6 
 
1
2 
 
5 
 
16 
 
10 
 
7 
 
0 
 
In our study the maximum  number of patients were in their 5th and 6th 
decade. The mean age of these patients was 58.6 years and  ranged from 36 to 
81 years. 
Table III 
Family History Of Diabetes Mellitus 
N = 100 
Family History of diabetes mellitis No. 
PRESENT 70 
 
ABSENT 30 
 
 
Out of the 100 patients family history of diabetes was seen in 70 cases. 
The remaining 30 did not have diabetes in the family. 
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Table IV 
Random Blood Glucose Levels 
N = 84 
above 200mg% below 200mg% 
                               27                                 57 
 
Random Blood glucose levels were noted and 27 patients out of the 100 
cases were found to have glucose levels above 200mg% and 57 cases were 
seen to be  below 200mg%.The values for the remaining 16 cases were not 
available. 
Table V 
Risk Factors 
N = 100 
FACTORS No. 
Peripheral neuropathy 52 
Hypertension 48 
History of diabetic foot Ulcer 35 
History of Amputations 25 
History of Trauma 13 
History of Retinopathy 6 
Peripheral vascular disease 12 
 
Peripheral neuropathy was found to be the most common(52%) 
comorbid condition among the 100 patients studied.  History of amputation was 
seen in 25 cases.  
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Table VI 
Wagner `S Classification of Diabetic Foot Ulcer 
N = 100 
Grade No. 
I 21 
II 64 
III 14 
IV 1 
V 0 
 
MICROBIOLOGICAL DATA 
Table VIII 
Frequency of Isolates 
N  = 142 
Organism No % 
1. S.aureus 
2. P. aeruginosa 
3. K. pneumonia 
4. K.oxytoca 
5. Pr. vulgaris 
6. Pr. mirabilis 
7. CONS 
8. E.coli 
9. M. morganii 
10. C.freundi 
11. Strep pyogenes 
12. Enterococci 
13. Bacteroides 
14. Peptostreptococcus 
41 
17 
20 
7 
4 
11 
10 
14 
1 
1 
8 
4 
2 
2 
28.8 
11.9 
14.0 
4.0 
2.8 
7.7 
7.0 
9.8 
0.7 
0.7 
5.6 
2.8 
1.4 
1.4 
 
Total number of 142 isolates were obtained from the 100 cases of 
diabetic foot ulcer . S. aureus was found to be the most common gram positive 
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cocci (28.8%). Among gram negative bacilli Klebseilla spp were isolated in 27 
cases (18%). Followed by P. aeruginosa in 17 cases. (11.9%) Anaerobic 
bacteria  isolated from Grade III lesions were Bacteroides 2 (1.4%) and 
Peptostreptococcus 2 (1.4%) 
Table IX 
Poly VS Monomicrobial 
N= 100 
MONOMICROBIAL POLYMICROBIAL AVE: ORGANISM PER CASE 
58 42 1.42 
 
Among the 100 cases 58 foot ulcers were found to be monomicrobial 
and 42  were polymicrobial in nature. In an average 1.42 organisms per case 
was obtained. 
Table X 
Gram positive cocci Vs Gram negative bacilli       
N = 142 
Organism No. % 
Gram positive cocci  65 45.1 
Gram negative bacilli 77 54.3 
 
Out of the 142 isolates obtained from the diabetic foot ulcers 65 (45.1%) 
cases were found to be Gram positive cocci and 77 (54.3%) were Gram 
negative bacilli. 
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Table XI 
Antibiotic Sensitivity Pattern of Gram Positive Cocci 
N = 63 
 ANTIMICROBIAL 
AGENT 
S. AUREUS
N = 41 
SEN. % 
CONS 
N = 10 
SEN% 
STREP 
PYOGENES 
N = 8 
SEN% 
ENTEROCOCCI 
N = 4 
SEN% 
1 
2 
3 
4 
5 
6 
7 
AMOXYCILLIN 
CIPRO 
GENTAMICIN 
CEPHALEXIN 
CEFATAXIME 
VANCOMYCIN 
ERYTHROMYCIN 
8 
27 
25 
20 
26 
41 
- 
20% 
66% 
61% 
49% 
63% 
100% 
- 
7 
9 
7 
9 
10 
10 
5 
70% 
90% 
70% 
90% 
100% 
100% 
50% 
6 
8 
7 
6 
7 
8 
5 
75% 
100% 
87% 
75% 
67% 
100% 
62% 
2 
4 
3 
1 
3 
4 
3 
50% 
100% 
75% 
25% 
75% 
100% 
75% 
 
Out of the 63 Gram positive isolates identified from the diabetic foot 
ulcers all were found to be sensitive to vancomycin. Among the isolates of S. 
aureus  only 20% (8 cases) were sensitive to amoxicillin, 66% of S. aureus 
were sensitive to ciprofloxacin.  
Table XII 
Antibiotic Sessitivity Pattern  of Gram  Negative Bacilli 
N=75 
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1 
2 
3 
4 
5 
6 
AMIKACIN 
CIPRO 
CEFTRIOXON 
CEFTAZDIME 
IMIPENAM 
PIP/ TAZO 
11 
4 
9 
12 
18 
11 
55% 
20% 
45% 
65% 
90% 
55% 
5 
4 
2 
2 
5 
7 
71% 
57% 
29% 
29% 
71% 
100% 
7 
4 
6 
4 
17 
13 
50% 
28% 
43% 
28% 
78% 
93% 
4 
2 
2 
4 
6 
9 
23% 
12% 
12% 
23% 
35% 
53% 
2 
3 
2 
2 
3 
4 
50% 
75% 
50% 
50% 
75% 
100% 
9 
7 
9 
8 
10 
9 
82% 
64% 
82% 
73% 
91% 
82% 
 
Among the 75 isolates of Gram negative bacilli isolated from the 
diabetic foot ulcers Imipenam showed good sensitivity. Klebseilla Spp and 
Proteus spp showed 80-90% sensitivity towards Imipenam.  
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Screening for MRSA 
Table XIII 
Using oxacillin disc (1 ug) 
N = 41 
ZONE(mm) NO: of isolates % 
> 14 MSSA 24 58.5 
< 10 MRSA 17 41.5 
 
All the 41 isolates of  S. aureus were screened for methicillin resistance 
using oxacillin disc(1ug)  and out of them 17(41.5%) were found to have a 
zone of inhibition less than 10mm for oxacillin (1ug) .   
Table XIV 
Using Cefoxitin disc (30ugs) 
N = 41 
ZONE(mm) NO:of isolates % 
> 20 MSSA 23 56 
< 19 MRSA 18 44   
All the 41 isolates of  S. aureus were then further confirmed for 
methicillin resistance using cefoxitin disc (30ug)   
Table XV 
PCR FOR mecA GENE IDENTIFICATION 
N = 18 
Total isolates of S.aureus mec A present mec A absent 
18 18 nil 
 
The 18 strains which showed resistance to Cefoxitin were subjected to 
mecA gene identification using the conventional PCR technique. All of the 18 
isolates  were positive for mecA gene.  
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SCREENING FOR ESBL 
Table XVI 
Resistance to Two 3rd Generation Cephalosporins 
N = 75 
ORGANISM CEFTRIOXONE CERTAZIDIME 
K. pneumonia 
K.oxytoca 
E.coli 
Pr. vulgaris 
Pr. mirabilis 
P. aeruginosa 
11 
5 
8 
2 
3 
15 
10 
5 
10 
1 
3 
15 
 
Out of 75 isolates of Gram negative bacilli 40 were found to be resistant  
to two 3rd generation cephalosporins namely ceftrioxone and ceftazidime. The 
remaining were sensitive to at least one of the above 3rd generation 
cephalosporins.  
Table XVII 
Resistant gram negative bacilli 
N = 40 
Enterobactericeae Pseudomonads 
25 15    
Out of the 40 isolates  25 were from the Enterobactericeae family and 
the remaining 15 were Psedomonads.  
All the 25 isolates of Enterobactericeae were subjected to  Double disc 
synergy test , Phenotypic confirmation test and MIC reduction test  to detect 
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the presence of  ESBL producers.The resistant Pseudomonads were subjected 
to  Combined disc synergy test for the detection of Metallobetalactamases 
(MBL)  
Table XVIII 
Double Disc Synergy  Test 
N = 25 
No. of Isolates Positive Negative 
25 20 5 
  
In the Double  disc  synergy method for identification of ESBL, 
cefataxime (30mcg) and amoxicillin/clavulanate (20ug/10ug) was used and  out 
of  the  25 isolates of enterobactericeae  20 were identified as ESBL producers. 
ESBL Confirmatory test 
TABLE XIX 
Combined Disc Test 
N = 25 
No.of Isolates Positive Negative 
25 22 3 
  
Using the combined  disc method as described in CLSI guidelines, out 
of the 25 isolates of enterobactericeae 22 were found to be ESBL producers. 
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Table XX 
Minimum Inhibitory Concentration (MIC) of isolates to Ceftazidime (μg/ml)      
N = 25 
 Total 2 4 8 16 32 64 128 256 512 1024 
Klebsiella 
pneumoniae 11 0 0 0 0 0 1 2 3 3 2 
Klebsiella 
oxytoca 2 0 0 0 0 0 0 1 1 0 0 
E.coli 7 0 0 0 0 0 1 1 2 3 0 
P.mirabilis 4 0 0 0 0 0 0 0 0 1 3 
P.vulgaris 1 0 0 0 0 0 0 0 0 0 1 
 
Minimum inhibitory concentration of Ceftazidime for the ESBL 
producing organisms in the study was between 64 µg/ml of agar to 1024 µg/ml 
of agar Reduction of  (MIC) of isolates  to Ceftazidime with 2μg/ml Clavulanic 
acid. 
TABLE XXI 
MIC Reduction in the presence of Ceftazidime with 2 μg/ml Clavulanic acid in 
Agar (N=25) 
 Concentration of Ceftazidime with 2μg/mlClavulanic acid in Agar 
(µg/ml) 
Total 0.5 1 2 4 8 16 32 64 128 
Klebsiella 
pneumoniae 11 1 0 5 2 1 2 0 0 0 
Klebsiella 
oxytoca 2 0 0 0 0 0 1 1 0 0 
E.coli 7 0 0 0 1 2 3 1 0 0 
P.mirabilis 4 0 0 0 0 2 0 0 0 2 
P.vulgaris 1 0 0 0 0 0 0 0 1 0 
 
Minimum inhibitory concentration of Ceftazidime for the ESBL 
producing organisms in the study was between 0.5 µg/ml of agar to128 µg/ml 
of agar in the presence of clavulanic acid at a concentration of 2 µg/ml of agar 
showing 8 fold reductions in MIC. 
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Table XXII 
ESBLS PRODUCERS 
N = 75 
Isolates of Gram 
negative bacilli 
MIC 
REDUCTION 
Positive 
COMBINED 
DISC 
Positive 
ESBL% 
75 22 22 29.3% 
 
All the isolates of enterobacteriaceae screened as probable ESBL 
producers were tested with combined disc test and were subjected to MIC 
reduction test. Out of the 75 gram negative bacilli  22 were identified as ESBL 
producers in both methods.Hence the percentage of ESBL producers was 
29.3% 
TABLE XXIII 
CTX – M Gene Identification in Klebseilla SPP. 
N = 13 
ORGANISM 
 
 
NO: 
TESTED 
CTX-M- 
GENE 
PRESENT 
CTX-M 
GENE 
NEGATIVE 
% 
POSITIVE 
K.pneumonia 11 6 5 54.5 
K.oxytoca 2 0 2 _ 
 
       The CTX-gene responsible for the ESBL production was studied in the 
Klebseilla spp. Out of the 11 isolates of K.pneumonia 6(54.5%) were positive 
for the CTX-gene 
TABLE XXIV 
Screening for Metallobetalactamases  Producers Among Pseudomonads 
N = 15 
Isolates Positive Negative MBL% 
15 14 1 93.3 
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P. aeruginosa resistant to imipenam were screened for MBL production 
by the combined disc method using 750ug of EDTA. Out of 15 isolates 
14(93.3%)  isolates were positive for the test . 
Table XXV 
OUTCOME OF THE STUDY 
N= 62 
OUTCOME NO(%) MRSA ISOLATE 
ESBL 
ISOLATE 
MDR 
PSUEDO NON MRSA/ESBL 
HEALED 18(29%) 1 2 2 13 
FLAPSURGERY 14(22.5%) 3 3 1 7 
REGULARDRESSING 24(38.7%) 8 3 4 9 
AMPUTATION 6(9.6%) 3 2 0 1 
 
Outcome was noted in 62 patients only as the remaining did not come 
for regular follow up. Out of the 62 patients healing was seen in 18(29%) 
patients and among them one (0.5%) was positive for MRSA,two(1.1%) had 
ESBL in the ulcers and two(1.1%) lodged MDR Pseudomonads and the 
remaining13(72%) did not harbour any resistant organism .Various flap 
surgeries depending upon the nature of the ulcer was done in 14(22.5%) of the 
patients.Out of them 50% had resistant organisms in the ulcers (MRSA-
21.4%,ESBL-21.4% and MDR Pseudo-7%). 24(38.7%)  patients were on 
regular dressing at the end of the period of study. Their ulcers did not heal even 
after regular dressings. Among the patients 15(24%) had resistant organisms in 
their ulcers (MRSA-33%, ESBL -12%, MDR Pseudo -16%,). Amputation was 
done in 6 (9.6%) of the patients out of which 3 (50%) showed MRSA, 2 (33%) 
showed ESBL and one patient did not have any resistant organism.  
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DISCUSSION 
In the present study the total number of patients with diabetic foot ulcers 
were hundred. As per our study the total number of males were 53 and females 
were 47. The male to female ratio was 1:0.8. There were more number of males 
with diabetic foot ulcer than females in our study. This feature correlated with 
studies conducted by Dushyant  Singh gaur et al(33),Sharma et al (35) and Lea 
Renina Ilanes (31). 
The mean age of patients with diabetic foot ulcers in our study was 
58.6.This  observation was also made by Lea Renina et al.(31) and Gaur et al(33). 
In our study most patients were in their 5th decade of life ,this was in contrary 
to other studies by Sharma et al and Llanes et al who reported diabetic foot 
ulcers to be more common in the 6Th decade. 
Family history of Diabetes Mellitus was noted in 70% of the patients 
who took part in the study. Hence positive family history of Diabetes Mellitus 
was a significant factor in the development of foot ulcers in the patients. 
However family history of foot ulcers leading to foot ulcers in the sibling 
appeared only in eight patients. Poor glycaemia control (random blood glucose 
level >200mgs%) was found in 27% of the patients hence it is an important 
factor in wound healing. This finding was also noted by Sharma etal (35)  
The most common risk factor for the development of Diabetic foot 
ulcers among the patients was observed as peripheral neuropathy which was 
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seen in 52% of the patients. Neuropathy predisposes a diabetic to unrecognized 
injury due  to loss of sensation. Similar findings have also been reported by 
Llanes et al (31) and Sharma et al . (35) Patients also had co morbid conditions 
like hypertension, history of amputation and peripheral vascular disease 
indicating that ulcers develop from the interplay of multiple risk factors 
superimposed with infection. 
Most of the patients in the present  study presented with Wagner’s grade 
II ulcers. Llanes et al (31) and Sharma et al (35) also made similar observation. 
This might be because of increased awareness among patients about foot care 
and regular screening done for foot ulcers at our hospital. Also because the 
patients in our study come to the department regularly for medicines and 
dressing of the ulcers. 
The present study showed gram negative organisms (54.3%) to be more 
common in diabetic foot ulcers, this feature correlated with findings from 
studies done by Llanes et al (31), Shankar et al (27) and Bansal et al. However 
studies by Sharma et al (35) showed gram positive cocci to be more common 
among diabetic foot ulcers. S.aureus(28.8%) was found to be the most 
commonly isolated organism in our study ,this finding correlated with 
observations made by Llanes et al (31), Gaur et al (33) and Sharma et al (35) .In our 
study Klebseilla species(18%) was the most common gram negative organism 
which was contrary to other studies which have reported Pseudomonas to be 
the most common gram negative bacteria isolated from diabetic foot ulcers. 
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The polymicrobial nature of diabetic foot ulcers has been well 
documented by a number of authors like Llanes et al (31). Sharma et al (35). This 
feature was also noted in our study. The average organism per ulcers in our 
study showed 1.42 bacteria per case which was similar to findings by 
Vishwanathan et al(1.21) (36) and  a little lower than Bansal et al(1.57). This 
might have been due to the fact that  ulcers that we studied were mostly 
superficial ulcers and only few deeper ulcers were sampled. 
All the gram positive organism isolated in our study were sensitive to 
vancomycin, this observation was also made by Sharma et al. Good sensitivity 
to ciprofloxacin was noted among the gram positive cocci( >90%) but for 
S.aureus (66%). Bansal et al also made similar observation. Sensitivity to 3rd 
generation cephalosporin was between 60 to 70%. Amoxycillin was the least 
sensitive drug among the gram positive cocci. 
Among the gram negative isolates good sensitivity was seen for 
imipenem (>85%). Resistance to 3rd generation cephalosporin was high among 
the gram negative bacilli (60%) this feature was also noted by Gadepalli et 
al.(36)  High rate of antibiotic resistance seen in our study may be due to the fact 
that ours is a tertiary care hospital with widespread usage of broad spectrum 
antibiotics leading to selective survival advantage of pathogen. Four anaerobes 
(2.8%) were isolated from grade III lesions.  
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Oxacillin resistance in isolates of S.aureus was used as a screening test 
for detection of MRSA in our studies but as the sensitivity and specificity of 
the test as reported by Swenson et al (1) was 86% and 74% respectively.  We 
followed CLSI guidelines of using Cefoxitin (30ug) disc diffusion test for 
predicting the presence of the mecA gene which is responsible for methicillin 
resistance in S.aureus. Hence  in our study MRSA identification using cefoxitin 
disc (30ug) correlated with all the mecA positive S.aureus. Studies done by 
Swenson et al (1) noted that this test had a sensitivity and specificity of 100%. 
Cefoxitin disc method has been shown to be superior to Oxacillin disc method 
for detection of MRSA by authors like Sandrin Roisin et al.(16). 
The percentage of MRSA isolated in our study was 44% among the 
Staphylococcus aureus isolated  which was closer to studies done by 
Tentoloisis al(28) (40%) and Lipsky et al(29). However it was lower than studies 
done by Gadepalli (56%). Lipsky also noted that colonisation with MRSA was 
more common in Grade1 lesions.  Gadepalli observed presence of MRSA 
doubles the healing time in diabetic foot ulcer. This observation was also made 
in our studies as 33% of the patients coming for dressing had MRSA. 
In our study screening for ESBL producers in gram negative bacilli has 
been done using two 3rd generation cephalosporin as first line drugs in routine 
antibiogram as per CLSI guidelines. All isolates resistant to both the drugs  
were subjected to double disc synergy test but as this test has a lower 
sensitivity, phenotypic combined disc test was done. This method for 
identification of ESBL producers has been done in a numbers of studies like 
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Ami Variya et al.(39) In our study MIC for most of the ESBL producers was 
seen to be high (>64ug/ml)  Similar feature was seen by Amit jain et al.(60). 
CTX-M gene responsible for the production of betalactamase was 
identified in 6 out of 11 strains of Klebseilla spp, which was 54.5%, this feature 
correlated with studies done by Baby Padmini  et al.(61).  They also found this 
gene to be most common in South India. In our study  CTX-M positive 
Klebseilla were seen to have associated resistance to fluroquinalones, this 
finding was also observed by Baby Padmini et al. Overall the percentage of 
ESBL in our study was 39.3% among the enterobactericeae studied and 29.3% 
among the gram negative bacilli and this feature correlated with other studies 
done on diabetic foot ulcers by Ami Variya et al (39). 
In our study the percentage of MBL producing Pseudomonads among 
the gram negative bacilli was 18.6% and this feature  was also noted by Ami 
Varaiya et al (20%)(39).      
The outcome of the ulcers was based on a number of factors. Healing 
was seen more in patients with grade I ulcers with good glycaemia control and 
those without resistant organism in their foot ulcer. Regular dressing for non 
healing ulcers was more common among patients with other co morbid 
conditions and also resistant organism in the ulcers which was seen in (24%) of 
the ulcers. Amputation was seen in 9.6%  of the patients most of them had 
grade III ulcers and 50% of the ulcers showed MRSA suggesting the higher 
rates of amputation in patients with MRSA. This feature was also noted by 
Gadepalli et al(36) and Lipsky et al.(32). 
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SUMMARY 
The present study showed gram negative organisms (54.3%) to be more 
common in diabetic foot ulcers. S.aureus (28.8%) was found to be the most 
commonly isolated organism in our study and Klebseilla species(18%) was the 
most common gram negative organism. P.aeruginosa was isolated from 12% of 
the cases. Four anaerobes (2.8%) were isolated from grade III lesions.  The 
average organism per ulcers in our study showed 1.42 bacteria per case. 
All the gram positive organism isolated in our study were sensitive to 
vancomycin. Good sensitivity to ciprofloxacin was noted among the gram 
positive cocci ( >90%) but for S.aureus (66%). 
Among the gram negative isolates good sensitivity was seen for 
imipenem (>85%).  Resistance to 3rd generation cephalosporin was high among 
the gram negative bacilli (60%).  The most common risk factor for the 
development of Diabetic foot ulcers among the patients was observed as 
peripheral neuropathy which was seen in 52% of the patients.  
The percentage of MRSA in our study was noted to be 44%.  MecA 
gene was positive in 18 strains which was 100% of the isolates of 
Staphylococcus aureus tested using conventional PCR technique.  
ESBL producing isolates were selected based on their resistance to two 
3rd generation cephalosporin.  The presence of the gene responsible for the 
production of ESBL  namely CTX-M gene was present in 6 out of 13 isolates 
of Klebseilla spp.which was 54.5%.  In our study the percentage of ESBL 
producers was 29.3%. 
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CONCLUSION 
The foot problem in diabetic patients is multifaceted  and three great 
pathologies come together in its development namely neuropathy, ischaemia 
and infection. Our study  addresses infection in the foot ulcers of patients 
attending the Institute of Diabetology at Kilpauk Medical College &,Hospital   
Chennai. 
• We found the diabetic foot ulcers to be polymicrobial in nature and 
Gram negative bacteria(54.3%) to be more common then gram positive 
bacteria (45.1%).However Staphylococcus aureus(28.8%) was seen as 
the most common bacterial pathogen followed by Klebseilla spp(18%) 
and Pseudomonads.(12%) 
• Our studies showed the foot ulcers to be higher in patients with diabetes 
in the family and who had co morbid risk factor of which neuropathy 
was the most common. Poor glycaemia control also appeared as a 
significant factor for healing of the ulcer.   
• On analyzing the antibiotic sensitivity pattern of the isolates we 
observed an alarming number of multidrug resistant organisms in the 
diabetic foot ulcers .   44% of S. aureus isolated were MRSA, 39.3% of 
the enterobactericeae  were ESBL producers and 82.3% of 
Pseudomonads were  MBL producers.  .  
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• The high rates of antibiotic resistance observed in the present study may 
be due to the fact that ours is a tertiary care hospital with widespread 
usage of broad spectrum antibiotics leading to selective survival 
advantage of pathogens. 
• The outcome of the patients depended on a number of factors like grade 
of the ulcer, associated co-morbid conditions and the presence of 
resistant pathogen. 
• Our study showed that resistant isolates to be present in 54 cases of the 
diabetic foot ulcers. MRSA was seen in 18 cases, ESBL in 22 cases and 
MBL producing Pseudomonads in 14 cases. 
• Our study showed that amputation was more common in ulcers which 
had MRSA(50%).Wound healing was delayed in patients with resistant 
bacteria-33% MRSA, 12% ESBL and 16% Multidrug resistant  
Pseudomonads. Healing of wound was maximum in grade I ulcers and 
those ulcers which did not show the presence of resistant bacteria 
namely 72% of the ulcers. 
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APPENDIX 
1. MacConkey agar:- 
This is a useful medium for the cultivation of enterobacteriaceae. It 
contains a bile salt to inhibit non-intestinal bacteria and lactose with neutral red 
to distinguish the lactose-fermenting coli forms from the lactose –non-
fermenting salmonella and shigella groups. The concentration of sodium 
taurocholate may be reduced to suit less tolerant organisms. The omission of 
sodium chloride from the medium prevents the spreading of Proteus colonies. 
Peptone                                                                                      20 g 
Sodium taurocholate, commercial                                                5 g 
Water                                                                                        1 litre 
Agar                                                                                            20 g 
Neutral red solution, 2% in 50% ethanol                                 3.5 ml 
Lactose, 10% aqueous solution                                             100 ml 
 
Dissolve the peptone and taurocholate (bile salt) in the water by heating. 
Add the agar and dissolve it in the steamer or autoclave. If necessary, clear by 
filtration. Adjust the pH to 7.5. Add the lactose and the neutral red, which 
should be well shaken before use, and mix. Heat in the autoclave with ‘free 
steam’ (c. 100o C) for 1hr., then at 115o C for 15 min. Pour plates. 
2. Nutrient agar:- 
                                                                                               Gm/L 
Peptic digest of animal tissue                                                  5.00 
Beef extract                                                                             1.50 
Yeast extract                                                                            5.00 
Agar                                                                                       15.00 
 
Dissolve the contents in water and mix by heating Autoclave at 121o C 
for 15 minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml of 9 cm dia. Petridishes 
to give 4 mm thickness. 
3. Blood agar:- 
Sterile sheep blood                                                              50 ml 
Peptone                                                                                10 g 
Beef extract                                                                             3g 
Sodium chloride                                                                     5 g 
Distilled water                                                                 1000 ml 
 
Autoclave the nutrient agar base at 121o C for 15 minutes and blood with 
sterile precautions and distribute in Petri dishes. 
For Anaerobic culture blood agar was supplemented with vitK(10ug/ml) 
and hemin(5ug/ml). 
4. Muller Hinton agar:-   
Beef infusion   300  ml 
Casein Hydrolysate   17  gm 
Starch    1.5 gm 
Agar  10  gm 
Distilled water 1000 ml 
Emulsify the starch in a small amount of cold water, pour into the beef 
infusion and add the casein-Hydrolysate and the agar. Make up the volume to 
1000 ml (1 litre) with distilled water. Dissolve the constituents by heating 
gently at 100o C with agitation. 
 Adjust the pH to 7.4. Dispense in screw-capped bottles and sterilize by 
autoclaving at 121 o C for 20 minutes. 20 to 25 ml of it is poured into 
petridishes of 9 cm diameter to give a thickness of 4mm. 
5. McFarland’s Turbidity Standard for inoculum preparation 
A Barium sulphate 0.5 McFarland standards was prepared as follows 
1. A 0.5 ml of 0.048mol/L of Barium chloride was added to 99.5 ml of 
0.18 mol/L of H2SO4 with constant stirring to maintain a suspension.  
2. Correct density of the turbidity standard was verified by using a 
spectrophotometer. The absorbance of 625nm should be 0.08 to0.10 for 
the 0.5 McFarland standards. 
3. The Barium sulphate suspension was transferred in 4-6 ml to a screw 
capped tube of the same size as those used in growing or diluting the 
bacterial inoculam. 
4. These tubes were tightly sealed and stored in the dark at room 
temperature. 
5. The Barium sulphate turbidity standard was vigorously agitated before 
each use and inspected for a uniform turbid appearance. 
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Differentiating Characters of  isolates commonly seen in diabetic foot ulcer For Gram negative Bacteria[GNB} 
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Escherichia coli + - + LF + A/A  NA + + - 
Not 
utilised - + + + + + 
Klebsiella Pneumonia - - + LF - A/A NA + - + utilised + + + + + + 
Klebsiella oxytoca - - + LF + A/A NA + + - utilised + + + + + + 
Proteus. 
species + - + NLF + 
K/A 
with 
H2S
G + + - + + + - + - - 
Pseudomonas .aeruginosa + + + NLF + K/K NA 
 
+ 
 
  utilised  - - - + - 
M.morganii + - + NLF + K/A G  + 
 
+ 
 
- 
Not 
utilised 
 
+ + - - - - 
C.freundi + - + NLF + A/A NA  + 
 
+ 
 
- 
 
utilised 
 
+/- + + + + + 
 
Note:   A/A = Acid slant / Acid butt  
K/A = Alkali slant / Acid butt 
K/K = Alkali slant / Alkalibutt 
 
+   = Positive,    
-    =        Negative 
NA =     Not applicable  
ZONE SIZE INTERPRETATIVE CHART IN ACCORDING TO CLSI 
Kirby-Bauer Chart 
Sl. 
No. 
Drug Disk 
Content 
mcg 
Resistant 
mm or 
less 
Intermediate 
mm 
Sensitive 
mm or 
more 
1 Amoxycillin 10 mcg 14 mm 15-16 mm 17 mm 
2 Co-trimoxazole 1.25+3.75 10 11-15 16 
3 Cephalexin 30 14 15-17 18 
4 Norfloxacin 10 12 13-16 17 
5 Ciprofloxacin 5 15 16-20 21 
6 Gentamycin 10 12 13-14 15 
7 Cefotaxime 30 14 15-22 23 
8 Ceftriaxone 30 13 14-20 21 
9 Ceftazidime 30 14 15-17 18 
10 Amikacin 30 14 15-16 17 
11 Imipenam 10g < 13 14-15 > 16 
 
 
 
DIABETIC FOOT ULCER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPECIMEN COLLECTION 
 
 
 
 
 
 
 
 
 
 
 
 
1. Sterile Swab  
 
2. RCM Broth 
 
 
Amoxycillin
Ciprofloxacin
Ceftrioxone Imipenam
Amikacin
PIP / TAZO
Ceftazidime
SPECIMEN PROCESSING   
 
INOCULATION INTO PRIMARY PLATES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBIOGRAM  
 
 
1 
2 
3 
 
1 – Nutrient Agar Plate 
2 – Mac Conkey Agar Plate 
3 – Blood Agar Plate 
 
 
 
DETECTION OF MRSA USING CEFOXITIN DISC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DETECTION OF mecA GENE IN MRSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular Marker - 100bp  
Lane 1 TO 11  - Sample 
Lane 12  - Positive Control 
Lane 13   - Negative Control 
Gel Percentage - 1.2% 
MRSA MSSA
COMBINED DISC SYNERGY TEST FOR ESBL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Cefatazidime 30 μgs. 
2. Cefatazidime 30 μgs + Clavulanic acid 10 μgs. 
 
 
COMBINED DISC SYNERGY TEST FOR MBL PRODUCERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Imipenam 10 μg 
2. Imipenam 10 μg + EDTA (750 μg)  
 
2 1
1 2
 
 
MIC OF CEFTAZIDIME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REDUCTION OF MIC OF CEFTAZIDIME IN THE 
PRESENCE OF CLAVULANIC ACID (2μ/ML) 
 
 
 
 
 
 
 
 
 
 
 
DETECTION OF  CTX – M GENE IN KLEBSEILLA SPP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular Marker - 100bp  
Lane 1 TO 8, 11-13 - Sample 
Lane 9   - Positive Control 
Lane 10   - Negative Control 
Gel Percentage - 1.2% 
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Risk Factors
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Chart 4 
Wagnar's Classification of Diabetic foot ulcers
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Chart 6 
Antibiotic Sensitivity Pattern of Gram Positive Cocci
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Chart 7 
The Antibiotic Sensitivity pattern of gram negative 
bacilli
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ID.NO D.NO AGE SEX DURATION FAMILY HISTORY RISK FACTOR H/O HOSPITAL ULCER SITE GRADE BLOOD GLUCOSE LEVEL ISOLATE P/M MRSA  ESBL MDR PSEUDO OUTCOME
18/08 1/8 58 M 1 Year NO HT NO Rt dorsom II 186% S.aureus ,.Koxytoca P NO NO NO HEALED
67/08 2/8 64 F 5 Months NO HT NO Rt bigtoe II 298 mg% s.aureus  M NO NO NO NO FOLLOW UP
56/08 3/8 51 M 1Year NO _ NO Rt dorsom II 260 mg% S.aureus,Pseudo P NO NO YES HEALED
459/06 4/8 65 M 2 Years Yes H/o previous ulcer NO Rt dorsom III 99 mg% Kp,Pv P NO YES NO AMPUTATION
48/08 5/8 68 M 10 Years Yes PN, Retinopathi  NO Lt dorsom II 95% S.aureus M NO NO NO HEALED
6/7 6/8 58 F 22 Years NO HT, AMP NO Rt dorsom II 154% S.aureus,Pseudo P YES NO YES FLAP SURGERY
49/08 7/8 71 M 8Years Yes HT, PN, AMP NO Rt G‐toe II 83 mg% Kp,Pv P NO YES NO NO FOLLOW UP
296/07 8/8 56 F 7 Years NO H/o previous ulcer NO Rt G‐toe II 187 mg% S.aureus M YES NO NO HEALED
241/07 9/8 39 F 2 Years Yes PN NO Rt dorsom II 123 mg% P.mira M NO NO NO NO FOLLOW UP
24/07 10/8 46 F 15 Years Yes H/o previous ulcer trauma NO Lt G toe II 165 mg% Pseudo M NO NO YES HEALED
64/07 11/8 70 F 10 Years NO Ulcer, HT NO Rt 3rd toe II 116 mg% Pseudo M NO NO YES NO FOLLOW UP
70/08 12/8 61 M 20 Years NO PN Ulcer NO Lt dorsom II 170 mg% Kp M NO YES NO NO FOLLOW UP
48/08 13/08 68 M 10 Years Yes Ulcer, PN NO Lt G toe II 152 mg% S.aureus,M.morganii P YES NO NO NO FOLLOW UP
32/08 14/08 43 M 20 Yes HT, PN, Ulcer trauma  Yes Rt G‐toe II 272 mg% Pseudo,E,coli P NO YES YES NO FOLLOW UP
77/08 15/08 57 F 2 Yes Ulcer, Amp, trauma NO Rt toe I 100 mg% Strep.pyogenes P NO NO NO HEALED
71/08 16/08 47 M 2 Months NO trauma NO Rt G‐toe II _ Enterococci M NO NO NO NO FOLLOW UP
73/08 17/08 50 F 3 NO Ht, Ulcer, Amp NO Rt plantor III 192 mg% S,aureus M NO NO NO NO FOLLOW UP
88/07 18/08 58 M 2 NO Uas, PN NO Rt ankle II _ K.oxytoca M NO NO NO HEALED
19/08 39 M 4 Years Yes Ulcer NO Rt G‐toe II _ S.aureus ,Kp P NO YES NO NO FOLLOW UP
73/07 20/08 57 M 12 Yes Ht, PN, Ulcer, Amp NO Rt G‐toe III 290 mg% Strep.pyogenes P NO NO NO NO FOLLOW UP
22/08 21/08 64 F 7 Yes PN Amp NO Lt G toe II 197 mg% K.oxytoca,Pseudo P NO YES YES NO FOLLOW UP
72/06 22/08 55 M 8 NO Ht, PN, Ulcer NO Lt ankle II 148 mg% S,aureus,P.mira P YES NO NO FLAP SURGERY
8/7 23/08 40 M 6 Yes PN, Amp trauma NO Gt G toe II _ Pseudo M NO NO YES NO FOLLOW UP
95/08 24/08 50 F 4 Yes HT, PN NO Rt foot II 209 mg% Enterococci M NO NO NO HEALED
13/08 25/09 72 F 14 Years Yes HT, Retinopathy ulcer  NO Lt G toe II 217 mg% CONS,E.coli P NO YES NO FLAP SURGERY
95/08 26/09 84 M 10 Yes PN Ulcer NO Lt G toe II 159 mg% E.coli M NO NO NO NO FOLLOW UP
76/08 27/09 48 M 10 Yes Ulcer, Amp NO Rt great toe,  II 202 mg% S.aureus ,Kp P NO YES NO HEALED
_ 28/09 72 M 22 Years Yes HT, AMP NO Lt dorsom II 319 mg% S,aureus M YES NO NO NO FOLLOW UP
8/8 29/09 61 F 11 Years NO PN NO Rt dorsom II _ C.freundi,CONS P NO NO NO NO FOLLOW UP
29/08 30/09 54 M 7 Years NO HT Vas NO Lt G toe II 98 mg% Pseudo M NO NO YES REG DRESSING
_ 31/09 69 M 10 Yes HT, Vas, PN, Ulcer, Amp Yes Rt dorsom III 498 mg% S,aureus,Pseudo P YES NO NO AMPUTATION
27/08 32/09 62 M 5 NO HT, PN NO Rt ankle II 244 mg% S,aureus M YES NO NO NO FOLLOW UP
 28/08 33/09 41 F 2 NO PN NO Lt 3rd toe I 164 mg% Pseudo M NO NO NO HEALED
_ 34/09 60 F 10 Yes PN NO Rt platar II _ S,aureus M YES NO NO REG.DRESSING
7/7 35/09 52 M 12 Yes PN Yes Rt dorsom II 83% S,aureus M NO NO NO HEALED
29/07 36/09 54 F 5 Months NO PN NO Lt dorsom II 294 mg% S,aureus,E.coli P YES NO NO FLAPSURGERY
6/9 37/09 50 F 25 Years Yes Ulcer, Amp Yes Lt 2nd toe stamp III 119 mg% CONS,P.mira,Kp P NO YES NO amputation
9/9 38/09 55 F 5 Years NO PN NO Rt G‐toe I 190 mg% S.aureus M NO NO NO HEALED
4/9 39/09 54 M 15 Years Yes HT, PN, Ulcer Yes Rt Little toe II 173 mg% Strep.pyogenes M NO NO NO NO FOLLOW UP
8/8 40/09 67 M 10 Yes Vas ulcer NO Rt G‐toe II 214 mg% CONS M NO NO NO NO FOLLOW UP
35/09 41/09 30 F 2 Years NO PN NO Rt G‐toe I 117 mg% CONS M NO NO NO HEALED
36/09 42/09 60 F 11 Years Yes Amp NO Rt G‐toe II 155 mg% P.mira,E.coli P NO YES NO FLAP SURGERY
37/09 43/09 50 M 4 Years Yes HT, Vas NO Lt G toe II 232 mg% S.aureus M NO NO NO NO FOLLOW UP
24/09 44/09 50 F 8 Years Yes HT, Retinopathy  Yes Lt dorsom III 299 mg% S.aureus ,Kp P YES YES NO REG.DRESSING
74/09 45/09 39 M 1 Year Yes _ NO Rt 2nd toe I 124 mg% Strep.pyogenes M NO NO NO HEALED
40/09 46/09 55 F 4 Years NO HT NO Lt plantar I 200 mg% P.vulgaris M NO NO NO HEALED
31/09 47/09 45 F 2 Years Yes PN, Ulcer Yes Rt G‐toe II 292 mg% Pseudo,E,coli P NO NO YES NO FOLLOW UP
52/09 48/09 75 F 12 Years Yes HT, Retinopathy NO Lt ankle II 166 mg% S.aureus M NO NO NO FLAP SURGERY
57/09 49/09 58 F 4 Years NO HT NO Rt dorsom II 214 mg% S.aureus M NO NO NO NO FOLLOW UP
53/09 50/09 75 F 15 Years Yes Amp,PN NO Rt G‐toe III _ CONS,Pseudo P NO NO NO NO FOLLOW UP
57/09 51/09 58 F 7 Years Yes HT, PN NO Lt dorsom II 114 mg% E.coli,CONS P NO YES NO NO FOLLOW UP
59/09 52/09 65 F 11 Years Yes Ulcer, Vas dis  Yes Rt ankle III 184 mg% S.aureus ,Kp,CONS P YES YES NO AMPUTATION
60/09 53/09 65 M 2 Years NO HT NO Rt G‐toe I 112 mg% Strep.pyogenes M NO NO NO HEALED
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61/09 54/09 55 F 4 Months Yes PN trauma NO Rt 2nd toe I 97 mg% KP M NO NO NO HEALED
51/09 55/09 45 M 2 Years Yes PN HT NO Rt G‐toe II _ S.aureus ,Kp P NO NO NO FLAP SURGERY
64/09 56/09 69 F 12 Years NO Vas ulcer NO Lt G toe II 107 mg% P.mira,E.coli P NO YES NO FLAP SURGERY
65/09 57/09 40 F 6 Months Yes PN trauma NO Rt ankle I 124 mg% Strep.pyogenes M NO NO NO HEALED
43/09 58/09 79 M 12 Years Yes HT, Vas, Amp Yes Rt G‐toe III 412 mg% S.aureus M YES NO NO REG DRESSING
67/09 59/09 39 M 1 Year Yes PN NO Rt ankle I 98 mg% Enterococci M NO NO NO NO FOLLOW UP
68/09 60/09 55 F 2 Years Yes PN, Retinopathi  NO Lt dorsom II 142 mg% Pseudo,Kp P NO YES NO REG DRESSING
69/09 61/09 71 M 14 Years Yes HT, Amp NO Rt 3rd toe II 248 mg% Kp,CONS P NO NO NO FLAP SURGERY
73/09 62/09 53 M 7 Years NO Ulcer NO Rt dorsom II 166 mg% S.aureus M YES NO NO REG DRESSING
71/09 63/09 63 F 11 Years Yes Retinopathy NO Rt G‐toe II 112 mg% KP M NO NO NO FLAP SURGERY
70/09 64/09 60 F 1 Year NO PN NO Lt foot I 88 mg% Pseudo,E,coli P NO NO YES REG DRESSING
72/09 65/09 34 F 4 Months Yes PN NO Rt G‐toe I 107 mg% Enterococci M NO NO NO REG DRESSING
74/09 66/09 55 M 3 Years Yes Ht, Ulcer NO Rt dorsom II _ KP M NO NO NO REG DRESSING
75/09 67/09 64 M 14 Years Yes HT, PN, Amp,Vas Yes Rt 2nd toe III 226 mg% S.aureus M YES NO NO AMPUTATION
76/09 68/09 46 M 7 Months Yes trauma Yes Rt foot I 122 mg% S.aureus ,Kp P NO YES NO HEALED
79/09 69/09 47 M 2 Years Yes HT NO Lt foot I 107 mg% S.aureus M NO NO NO NO FOLLOW UP
80/09 70/09 45 F 4 Months Yes PN, trauma NO Rt G‐toe II 154 mg% P.mirabilis M NO YES NO REG DRESSING
78/09 71/09 65 M 17 Years Yes HT, PN, Amp NO Rt 2nd toe II 104 mg% Strep.pyogenes M NO NO NO NO FOLLOW UP
81/09 72/09 58 M 7 Months NO trauma NO Lt foot I _ P.mira,E.coli P NO NO NO REG DRESSING
43/09 73/09 41 M 2 Months Yes PN, trauma NO Rt ankle I 99 mg% S.aureus M NO NO NO REG DRESSING
35/09 74/09 68 M 10 Years Yes PN, Ulcer, Amp NO Rt foot IV 199 mg% S.aureus ,Kp P NO YES NO NO FOLLOW UP
_ 75/09 65 F 10 Years Yes Vas, ulcer NO Rt G‐toe II 273 mg% Pseudo M NO NO YES REG DRESSING
26/07 76/09 57 M 11 Years Yes Ht, PN, Ulcer, Amp NO Rt G‐toe II 227 mg% S.aureus M NO NO NO NO FOLLOW UP
32/09 77/09 60 F 4 Years NO HT,PN NO Lt foot II 180 mg% Pseudo,CONS P NO NO NO REG DRESSING
36/09 78/09 60 F 5 Years Yes HT,Amp Yes Rt G‐toe II 110 mg% KP M NO NO NO REG DRESSING
45/09 79/09 50 F 7 Years Yes PN Ulcer NO Rt G‐toe III _ S.aureus M NO NO NO NO FOLLOW UP
43/09 80/09 77 M 16 years Yes HT, PN, Ulcer NO Lt foot II 217 mg% Pseudo,E,coli P NO YES YES REG DRESSING 
41/09 81/09 53 M 4 Years Yes HT NO Rt foot II 117 mg% KP M NO NO NO REG DRESSING
38/09 82/09 76 F 11 Years Yes PN, Vas Amp NO Rt G‐toe II 194 mg% S.aureus M YES NO NO REG DRESSING
22/09 83/09 45 M 7 Months Yes HT NO Lt G toe II 122 mg% K.oxytoca M NO NO NO NO FOLLOW UP
23/09 84/09 60 F 2 Years Yes PN, trauma NO Lt foot I _ P.mira,E.coli P NO NO NO NO FOLLOW UP
37/09 85/09 69 M 1 Year NO Ht trauma NO GT foot II 145 mg% Strep.pyogenes M NO NO NO NO FOLLOW UP
56/09 86/09 55 M 2 Years Yes PN, HT NO Rt G‐toe II _ E.coli M NO NO NO NO FOLLOW UP
51/09 87/09 56 M 7 Years Yes HT, Vas Ulcer NO Rt 2nd toe II 247 mg% S.aureus M NO NO NO NO FOLLOW UP
51/09 88/09 39 M 4 Months Yes Ulcer NO Lt G toe I 114 mg% K.oxytoca M NO NO NO REG DRESSING
27/08 89/09 47 M 7 Years Yes Ulcer NO Lt foot II _ S.aureus M NO NO NO REG DRESSING
97/08 90/09 71 F 10 Years Yes Amp,ulcer NO Rt G‐toe III 202 mg% P.mira,Kp P NO NO NO AMPUTATION
70/09 91/09 64 M 11 Years Yes HT, PN Amp NO Rt G‐toe II _ S.aureus M NO NO NO NO FOLLOW UP
41/09 92/09 55 F 4 Years NO ht NO Rt dorsom II 147 mg% P.mirabilis M NO NO NO NO FOLLOW UP
47/09 93/09 74 F 12 Years Yes PN, HT, Retinopathy Yes Rt G‐toe III 226 mg% S.aureus ,.Koxytoca P YES NO NO REG DRESSING
34/09 94/09 60 F 7 Years Yes HT, PN, trauma NO Lt G toe II 134 mg% P.mirabilis M NO NO NO NO FOLLOW UP
17/09 95/09 64 M 11 Years Yes HT, PN Amp NO Rt 2nd toe II _ KP M NO NO NO NO FOLLOW UP
79/08 96/09 66 M 12 Years Yes HT, PN Ulcer NO Rt G‐toe III 119 mg% S.aureus,E.coli P NO NO NO NO FOLLOW UP
49/08 97/09 44 F 4 Months NO Ulcer NO Rt foot I 176 mg% S.aureus ,P,mira P YES NO NO REG DRESSING
66/09 98/09 75 F 8 Years NO Ht Retinopathy NO Rt G‐toe II 150 mg% K.oxytoca M NO YES NO REG DRESSING
74/08 99/09 66 M 7 Years Yes PN HT AMP NO Rt G‐toe III 249 mg% CONS,P.mira P NO NO NO NO FOLLOW UP
54/09 100/09 60 M 6 Years Yes PN, trauma NO Rt G‐toe II 172 mg% S.aureus M YES NO NO REG DRESSING
.
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Chart 2 
Age Distribution
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Chart 5 
Percentage of Isolates
S.aureus  P. aeruginosa  K. pneumonia  K.oxytoca Pr. vulgaris
 Pr. mirabilis  CONS  E.coli  M. morganii C.freundi
Strep pyogenes Enterococci Bacteroides Peptostreptococcus
Chart 6 
Antibiotic Sensitivity Pattern of Gram Positive Cocci
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Chart 7 
The Antibiotic Sensitivity pattern of gram negative bacilli
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Chart 8 
Percentage of MRSA Among S.aureus
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Chart 9 
Percentage of ESBL and MBL among GNB
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